ImmunityBio (IBRX) 10-Q 10 Sep 15 2015 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Jun. 30, 2015	Aug. 31, 2015
Document Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2015
Document Fiscal Year Focus	2,015
Document Fiscal Period Focus	Q2
Trading Symbol	NK
Entity Registrant Name	NANTKWEST, INC.
Entity Central Index Key	1,326,110
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Common Stock, Shares Outstanding		81,141,503

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2015	Dec. 31, 2014
Current assets:
Cash and cash equivalents	$ 120,437	$ 59,104
Accounts receivable, net	45	145
Prepaid expenses and other current assets	388	124
Total current assets	120,870	59,373
Investment in Inex Bio, Inc.		249
Property and equipment, net	310	211
Intangible assets, net	7,620	835
Other assets	3,757	160
Total assets	132,557	60,828
Current liabilities:
Accounts payable	3,180	1,131
Accrued expenses	2,618	311
Notes payable		265
Warrant derivative liability		177
Deferred revenue	241	521
Total liabilities	$ 6,039	$ 2,405
Commitments and contingencies (See Note 5)
Stockholders’ equity
Common stock	$ 7
Additional paid-in capital	256,515	$ 71,161
Accumulated deficit	(130,004)	(12,741)
Total stockholders’ equity	126,518	58,423
Total liabilities and stockholders’ equity	$ 132,557	60,828
Common Class A
Stockholders’ equity
Common stock		3
Total stockholders’ equity		$ 3

Condensed Consolidated Balance3

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Jun. 30, 2015	Dec. 31, 2014
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	100,000,000	80,000,000
Common Class A
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	0	75,470,414
Common stock, shares issued	0	61,094,367
Common stock, shares outstanding	0	61,094,367
Common Stock Class Undefined
Common stock, shares authorized	100,000,000	80,000,000
Common stock, shares issued	69,598,998	0
Common stock, shares outstanding	69,598,998	0

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Income Statement [Abstract]
Revenue	$ 91	$ 124	$ 211	$ 410
Operating expenses:
Research and development	1,745	243	2,348	363
Selling, general and administrative	82,429	1,052	114,023	2,113
Total operating expenses	84,174	1,295	116,371	2,476
Loss from operations	(84,083)	(1,171)	(116,160)	(2,066)
Other income (expense):
Interest income (expense), net	(15)	(231)	17	(470)
Other income, net			104
Fair value adjustment	(483)	6	(1,366)	(17)
Loss before income taxes	(84,581)	(1,396)	(117,405)	(2,553)
Income tax expense			(1)	(1)
Net loss	$ (84,581)	$ (1,396)	$ (117,406)	$ (2,554)
Net loss per share:
Basic and diluted	$ (1.29)	$ (0.19)	$ (1.85)	$ (0.49)
Weighted average number of shares during the period:
Basic and diluted	65,789,041	7,543,348	63,450,609	5,224,922

Condensed Consolidated Stateme5

Condensed Consolidated Statement of Shareholders' Equity (Unaudited) - 6 months ended Jun. 30, 2015 - USD ($) $ in Thousands	Total	Brink Biologics IncSpinout	Common Class A	Common Stock Class Undefined	Additional Paid-in Capital	Accumulated Deficit	Accumulated DeficitBrink Biologics IncSpinout
Beginning Balance at Dec. 31, 2014	$ 58,423		$ 3		$ 71,161	$ (12,741)
Beginning Balance, Shares at Dec. 31, 2014			61,094,367
Exercise of stock options	768		$ 1		767
Exercise of stock options, Shares			949,396
Stock-based compensation expense	104,564				104,564
Adjustment for 1.8515:1 stock split			$ 3		(3)
Warrants issued in conjunction with Inex Bio acquisition	5,170				5,170
Exercise of warrants	7,134				7,134
Exercise of warrants, Shares			4,106,492
Repurchase of common stock	(4,798)				(4,798)
Repurchase of common stock, Shares			(249,952)
Reclassification of warrant liability due to exercise	1,544				1,544
Conversion of Class A common stock to common stock			$ (7)	$ 7
Conversion of Class A common stock to common stock, Shares			(65,900,303)	65,900,303
Issuance of common stock less issuance costs of $28	70,976				70,976
Issuance of common stock less issuance costs of $28, Shares				3,698,695
Spinout of Brink Biologics, Inc.		$ 143					$ 143
Net loss	(117,406)					(117,406)
Beginning Balance at Jun. 30, 2015	$ 126,518			$ 7	$ 256,515	$ (130,004)
Beginning Balance, Shares at Jun. 30, 2015				69,598,998

Condensed Consolidated Stateme6

Condensed Consolidated Statement of Shareholders' Equity (Parenthetical) (Unaudited) - 6 months ended Jun. 30, 2015 $ in Thousands	USD ($)
Statement Of Stockholders Equity [Abstract]
Forward stock split of its outstanding common stock	1.8515
Stock issuance costs	$ 28

Condensed Consolidated Stateme7

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Cash flows used in operating activities:
Net loss	$ (117,406)	$ (2,554)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	1,042	103
Stock-based compensation expense	104,564	167
Change in fair value of warrant derivative liability	1,366	17
Change in value of note payable		377
Forgiveness of note receivable from related party		115
Loss incurred by Inex Bio	57
Gain on settlement of note payable	(133)
Changes in operating assets and liabilities, net of effects of acquisition:
Accounts receivable	100	190
Other current assets	(300)	58
Other assets	(3,592)	(19)
Accounts payable	2,048	(487)
Accrued expenses	2,312	75
Deferred revenue	(100)	(135)
Net cash used in operating activities	(10,042)	(2,093)
Cash flows used in investing activities:
Purchases of property and equipment	(152)	(17)
Purchase of Inex Bio Inc., net of cash acquired	(1,818)
Investment in intangible assets	(603)
Net cash used in investing activities	(2,573)	(17)
Cash flows provided by financing activities:
Proceeds from equity offerings, net of issuance costs	70,976	5,702
Finance issuance costs		78
Payments on notes payable	(132)	(52)
Proceeds from exercise of Class B common stock		23
Proceeds from exercise of warrants	7,134
Repurchase of common stock	(4,798)
Proceeds from exercise of stock options	768
Net cash provided by financing activities	73,948	5,751
Net increase in cash and cash equivalents	61,333	3,641
Cash and cash equivalents, beginning of period	59,104	351
Cash and cash equivalents, end of period	120,437	3,992
Cash paid during the period for:
Income taxes	1	1
Interest		52
Supplemental disclosure of non-cash investing and financing activities:
Conversion of debt and payables into common stock		1,339
Conversion of debt into Preferred Series C stock		1,000
Change in par value from $0.001 to $0.0001		$ 1
Cashless exercise of warrants	966
Other Owner Of Inex Bio Inc
Supplemental disclosure of non-cash investing and financing activities:
Issuance of warrants in Inex Bio, Inc. acquisition	$ 5,170

Condensed Consolidated Stateme8

Condensed Consolidated Statements of Cash Flows (Parenthetical) (Unaudited)	6 Months Ended
	Jun. 30, 2015$ / shares
Maximum
Change in par value	$ 0.001
Minimum
Change in par value	$ 0.0001

Description of Business and Bas

Description of Business and Basis of Presentation	6 Months Ended
	Jun. 30, 2015
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Description of Business and Basis of Presentation	1. Description of Business and Basis of Presentation Organization NantKwest, Inc. (the Company) was incorporated in Illinois on October 7, 2002 under the name ZelleRx Corporation. On January 22, 2010, the Company changed its name to Conkwest, Inc., and on July 10, 2015, the Company changed its name to NantKwest, Inc. The Company is a biotechnology company headquartered in San Diego, California with certain operations in Culver City, California. The Company is commercially developing targeted direct-acting immunotherapeutic agents for a variety of clinical conditions. The Company holds the exclusive right to commercialize activated natural killer (aNK) cells, a commercially viable natural killer cell-line, and a variety of genetically modified derivatives capable of killing cancer and virally infected cells. The Company owns corresponding U.S. and foreign composition and methods-of-use patents and applications covering the clinical use of aNK cells as a therapeutic to treat a spectrum of clinical conditions. The Company also licensed exclusive commercial rights to a portfolio of CD16 bearing aNK cells along with the corresponding U.S. and foreign composition and methods-of-use patents and applications covering the non-clinical use in laboratory testing of monoclonal antibodies as well as clinical use as a therapeutic to treat cancers in combination with antibody products. The Company has licensed or sub-licensed its cell lines and intellectual property to numerous pharmaceutical and biotechnology companies for such non-clinical uses. The Company retains exclusive worldwide rights to clinical and research data, intellectual property and know-how developed with the Company’s aNK cells, as well as the only clinical grade master cell bank. Principles of Consolidation The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary, Inex Bio, Inc. (Note 3), and have been prepared in accordance with accounting principles generally accepted in the United States of America. All intercompany accounts and transactions have been eliminated in consolidation. Domicile Change In March 2014, the Company entered into a definitive merger and share exchange agreement pursuant to which the Company redomesticated from the State of Illinois to the State of Delaware and the Illinois Company ceased to exist (the Redomestication). In connection with the Redomestication, the holders of Class A and Class B common stock received one share of Class A and Class B common stock of the Delaware Company, respectively, in exchange for fifteen shares of the Illinois Company. The holders of Series B preferred stock received one share of Series B preferred stock of the Delaware Company in exchange for one share of the Illinois Company. The holders of any options, warrants or other securities are subject to adjustment based on the ratio of one for fifteen. All share numbers and per share prices in the accompanying financial statements have been adjusted to reflect the 1 for 15 exchange. Liquidity As of June 30, 2015, the Company had an accumulated deficit of approximately $130,004. The Company also had negative cash flow from operations of approximately $10,042 during the six months ended June 30, 2015. The Company expects that it will likely need additional capital to further fund development of, and seek regulatory approvals for, its product candidates, and begin to commercialize any approved products. The Company is currently focused primarily on the development of immunotherapeutic treatments for cancers and debilitating viral infections using targeted cancer killing cell lines, and believes such activities will result in the Company’s continued incurrence of significant research and development and other expenses related to those programs. If the clinical trials for any of the Company’s product candidates fail or produce unsuccessful results and those product candidates do not gain regulatory approval, or if any of the Company’s product candidates, if approved, fails to achieve market acceptance, the Company may never become profitable. Even if the Company achieves profitability in the future, it may not be able to sustain profitability in subsequent periods. The Company intends to cover its future operating expenses through cash and cash equivalents on hand and through a combination of equity offerings, debt financings, government or other third-party funding, marketing and distribution arrangements and other collaborations, strategic alliances and licensing arrangements. Additional financing may not be available to the Company when needed and, if available, financing may not be obtained on terms favorable to the Company or its stockholders. While the Company expects its existing cash and cash equivalents will enable it to fund operations and capital expenditure requirements for at least the next twelve months, it may not have sufficient funds to reach commercialization. Failure to obtain adequate financing when needed may require the Company to delay, reduce, limit or terminate some or all of its development programs or future commercialization efforts or grant rights to develop and market product candidates that the Company might otherwise prefer to develop and market itself which could adversely affect the Company’s ability to operate as a going concern. If the Company raises additional funds from the issuance of equity securities, substantial dilution to existing stockholders may result. If the Company raises additional funds by incurring debt financing, the terms of the debt may involve significant cash payment obligations as well as covenants and specific financial ratios that may restrict the Company’s ability to operate its business. Forward Stock Split On July 10, 2015, the Company effected a 1.8515-for-1 forward stock split of its outstanding common stock. All applicable share data, per share amounts and related information in the financial statements and notes thereto have been adjusted retroactively to give effect to the 1.8515-for-1 forward stock split (Note 11). Unaudited Interim Financial Information The accompanying unaudited financial statements and notes have been prepared in accordance with accounting principles generally accepted in the United States (US GAAP) as contained in the Financial Accounting Standards Board (the FASB) Accounting Standards Codification (the Codification or ASC) for interim financial information. In the opinion of management, the interim financial information includes all adjustments of a normal recurring nature necessary for a fair presentation of the results of operations, financial position and cash flows. The results of operations for the three and six months ended June 30, 2015 are not necessarily indicative of the results for the full year or the results for any future periods. These financial statements should be read in conjunction with the audited financial statements and related notes for the year ended December 31, 2014 which are included in the Company’s final prospectus filed with the SEC on July 29, 2015 relating to our Registration Statement on Form S-1/A (File No. 333-205124) for the Company’s initial public offering.

Summary of Significant Accounti

Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2015
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. On an ongoing basis, the Company evaluates its estimates, including those related to the recoverability of patent costs included in intangible assets, valuation of warrants, stock-based compensation, the valuation allowance for deferred tax assets, allowance for doubtful accounts and business combinations. The Company bases its estimates on historical experience and on various other market-specific and relevant assumptions that it believes to be reasonable under the circumstances. Actual results could differ from those estimates. Risks and Uncertainties Concentration of Credit Risk Financial instruments, which potentially expose the Company to concentrations of credit risk, consist principally of cash balances on deposit with a bank, which exceed insured limits, and accounts receivable. The Company performs ongoing credit evaluations of customers’ financial condition, and the Company does not require collateral. There were five and seven customers that comprised the entire accounts receivable balance at June 30, 2015 and December 31, 2014, respectively. At June 30, 2015 and December 31, 2014, four and six customers, respectively, each had accounts receivable balances in excess of 10% of total accounts receivable. For the three months ended June 30, 2015, the Company derived revenue of $11 from one customer, representing 12% of the Company’s total revenue, compared to revenue of $19 from one customer, representing 15% of the Company’s total revenue for the three months ended June 30, 2014. For the six months ended June 30, 2015, the Company derived revenue of $27 from one customer, representing 13% of the Company’s total revenue, compared to revenue of $160 from one customer, representing 39% of the Company’s total revenue for the six months ended June 30, 2014. USPTO Proceeding In March 2009, the Company received a final rejection in one of the Company’s original patent applications pertaining to methods of use claims for NK-92 from the U.S. Patent and Trademark Office (the USPTO). The Company appealed this decision with the USPTO Board of Appeals and, in the fall of 2013, the Board of Appeals reversed the Examiner’s rejection of the claim to certain methods of use with NK-92, but affirmed the Examiner’s rejection of the remaining patent claims. In December 2013, the Company brought an action in the U.S. District Court for the Eastern District of Virginia to review the decision of the USPTO. On September 2, 2015, the U.S. District Court granted the USPTO’s motion for summary judgment. The Company has not yet determined whether it will appeal the decision. Intangible Assets Intangible assets consist of costs incurred in connection with patent applications (principally legal fees), patent purchases, trademarks related to the Company’s aNK cells and technology acquired in the asset purchase of Inex Bio. The Company calculates amortization expense for its patents and acquired technology using the straight-line method over the estimated useful lives, generally 4-15 years. Other intangibles, consisting of trademarks and copyrights, are considered to have indefinite lives and are not amortized but reviewed for impairment annually, or sooner under certain circumstances. The Company has no historical data to support a probable future economic benefit for patent applications, filing and prosecution costs other than for the Company’s aNK cells. Therefore, these patent-related costs are expensed as incurred and are included in selling, general and administrative in the statements of operations. The Company capitalizes patent application costs for those patents that are generating revenue currently. Should the Company experience a legal cost to defend a patent in the future, that cost would be capitalized only when it is part of the cost of retaining and obtaining the future economic benefit of the patent. Costs related to an unsuccessful outcome would be expensed. Fair Value of Financial Instruments The accounting standard for fair value measurements provides a framework for measuring fair value and requires disclosures regarding fair value measurements. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date, based on the Company’s principal or, in absence of a principal, most advantageous market for the specific asset or liability. The Company uses a three-tier fair value hierarchy to classify and disclose all assets and liabilities measured at fair value on a recurring basis, as well as assets and liabilities measured at fair value on a non-recurring basis, in periods subsequent to their initial measurement. The hierarchy requires the Company to use observable inputs when available, and to minimize the use of unobservable inputs, when determining fair value. The three tiers are defined as follows: · Level 1—Observable inputs that reflect quoted market prices (unadjusted) for identical assets or liabilities in active markets; · Level 2—Observable inputs other than quoted prices in active markets that are observable either directly or indirectly in the marketplace for identical or similar assets and liabilities; and · Level 3—Unobservable inputs that are supported by little or no market data, which require the Company to develop its own assumptions. Revenue Recognition and Deferred Revenue The Company derives substantially all of its revenue from non-exclusive license agreements with numerous pharmaceutical and biotechnology companies granting them the right to use the Company’s cell lines and intellectual property for non-clinical use. These license agreements generally include upfront fees and annual research license fees for such use, as well as commercial fees for sales of the licensees’ products developed or manufactured using the Company’s intellectual property and cell lines. The Company’s license agreements also may include milestone payments, although to date, the Company has not generated any revenue from milestone payments. The Company recognizes revenue when (i) persuasive evidence of an arrangement exists; (ii) delivery of the products and/or services has occurred; (iii) the fees are fixed or determinable; and (iv) collectibility is reasonably assured. When entering into an arrangement, the Company first determines whether the arrangement includes multiple deliverables and is subject to accounting guidance in Accounting Standards Codification (ASC) Subtopic 605-25, Multiple-Element Arrangements An element qualifies as a separate unit of accounting when the delivered element has standalone value to the customer. The Company’s agreements do not include a general right of return relative to delivered elements. Any delivered elements that do not qualify as separate units of accounting are combined with other undelivered elements within the arrangement as a single unit of accounting. If the arrangement constitutes a single combined unit of accounting, the Company determines the revenue recognition method for the combined unit of accounting and recognizes the revenue over the period from inception through the date the last deliverable within the single unit of accounting is delivered. License rights and non-contingent deliverables, such as knowledge transfer, do not have standalone value as they are not sold separately and they cannot be resold and, consequently are considered a single unit of accounting. Therefore, license revenue in the form of upfront payments is deferred and recognized over the applicable relationship period, which historically has been the estimated period of the Company’s substantive performance obligations or the period the rights granted are in effect. The Company recognizes a milestone payment when earned if it is substantive and the Company has no ongoing performance obligations related to the milestone. A milestone payment is considered substantive if it 1) is commensurate with either the Company’s performance to achieve the milestone or the enhanced value of the delivered item as a result of a specific outcome resulting from the Company’s performance to achieve the milestone; 2) relates solely to past performance; and 3) is reasonable relative to all of the deliverables and payment terms, including other potential milestone consideration, within the arrangement. The Company records any amounts received prior to satisfying the revenue recognition criteria as deferred revenue in the accompanying balance sheets. Stock-Based Compensation The Company measures and recognizes compensation expense for all stock-based payment awards made to employees, officers and directors based on the estimated fair values of the awards as of the grant date. The Company records the value of the portion of the award that is ultimately expected to vest as expense over the requisite service period. The Company also accounts for equity instruments issued to non-employees using a fair value approach under ASC Subtopic 505-50, Equity-Based Payments to Non-Employees. The Company values equity instruments and stock options granted using the Black-Scholes option-pricing model. The value of non-employee stock-based compensation is subject to periodic adjustments as the underlying equity instruments vest and is recognized as an expense over the term of the related financing or the period over which services are received. Basic and Diluted Net Loss per Share of Common Stock Basic net loss per share is calculated by dividing the net loss by the weighted-average number of common shares outstanding for the period. Diluted loss per share is computed similarly to basic loss per share except that the denominator is increased to include the number of additional shares that would have been outstanding if the potential common shares had been issued and if the additional common shares were dilutive. For all periods presented, potentially dilutive securities are excluded from the computation of fully diluted loss per share as their effect is anti-dilutive. The following table details those securities which have been excluded from the computation of potentially dilutive securities: Three and Six Months Ended June 30, 2015 2014 Series B convertible preferred stock — 8,888,597 Series C convertible preferred stock — 5,789,699 Class B common shares not exercised — 5,735,704 Outstanding options 8,447,209 3,425,769 Outstanding warrants 18,417,078 2,052,408 Total 26,864,287 25,892,177 Amounts in the table above reflect the common stock equivalents of the noted instruments. Comprehensive Loss The Company has no items of comprehensive income or loss other than net loss. Segment and Geographic Information Operating segments are defined as components of an enterprise (business activity from which it earns revenue and incurs expenses) for which discrete financial information is available and regularly reviewed by the chief operating decision maker in deciding how to allocate resources and in assessing performance. The Company’s chief operating decision maker (CODM) is its Chief Executive Officer. The Company views its operations and manages its business as a single operating and reporting segment

Investment In Inex Bio, Inc

Investment In Inex Bio, Inc	6 Months Ended
	Jun. 30, 2015
Schedule Of Investments [Abstract]
Investment in Inex Bio, Inc	3. Investment in Inex Bio, Inc. In April 2012, the Company made a strategic decision to enter into a License Agreement with Inex Bio, Inc. (Inex Bio), a Republic of Korea corporation (the Inex License Agreement). Under the Inex License Agreement, the Company provided Inex Bio with an exclusive license to the Company’s technology to be used in products only in certain Asian countries. In exchange for the Inex License Agreement, the Company received a $300 up-front license fee. In addition, the Company was eligible to receive milestone payments of up to $775 based upon completion of clinical trials and a 5% royalty on net sales of applicable products using the aNK cells. No milestone payments were due or received for the six months ended June 30, 2014 or 2015. In May 2012, the Company acquired 57,000 shares of Inex Bio for $249, which represented 22.2% of the outstanding shares and 17.4% of the fully-diluted shares of Inex Bio. The Company accounted for its investment under the equity method. The Company reviewed its investment for impairment in accordance with ASC Topic 320, Investments—Debt and Equity Securities. In February and March 2015, Inex Bio Holdings (Holdings), an entity owned fifty percent (50%) by Cambridge Equities, L.P., an entity in which Dr. Soon-Shiong, the Company’s chief executive officer and one of the Company’s directors, is the sole member of its general partner, and fifty percent (50%) Eragon Ventures, LLC, an entity of which Dr. Ji, one of our directors, is managing member, acquired 220,000 shares or 67.3% of Inex Bio from third party owners for $1,100. On March 30, 2015, the Company entered into a Stock Purchase Agreement with Holdings and the third party owners, pursuant to which the Company acquired all the remaining outstanding shares of Inex Bio not previously held by the Company. The Company paid to the other owners of Inex Bio cash of $1,500 and issued warrants to acquire 593,072 shares of the Company’s Class A common stock at an exercise price of $2.00 per share. The Company valued the warrants using the Black-Sholes option-pricing model with a stock price of $10.72 per share as of March 30, 2015, an expected term of 0.04 years, and a volatility of 80%. In April 2015, the Company received $1,185 for the full exercise of the warrants. The Company recorded the transaction as an asset purchase because Inex Bio was a shell corporation without any employees or other significant assets and did not meet the definition of a business under ASC Topic 805, Business Combinations. The purchase price paid to acquire Inex Bio from the other owners is as follows: Consideration Total Cash paid by Inex Bio Holdings Inc. $ 1,100 Cash paid by Company 1,482 Fair value of warrants 5,170 Aggregate purchase price $ 7,752 The following table summarizes the assets acquired and liabilities assumed: March 31, 2015 Cash $ 763 Intangible assets—reacquire rights of Company technology 7,199 Other assets 12 Investment in Inex Bio (221 ) Accounts payable (1 ) Total assets acquired and liabilities assumed $ 7,752 The license solely covers pending patent applications at this time. The Company will amortize the intangible assets related to the reacquired rights of the Company technology over 4 years, which represents the period until the next action date of the pending patent application in the territory of the license issued to Inex Bio. The Company paid Holdings cash of $6,400 and issued warrants to acquire 2,609,520 shares of the Company’s Class A common stock at an exercise price of $2.00 per share for their assistance in negotiating the acquisition of Inex Bio from the other owners. The Company valued the warrants using the Black-Sholes option-pricing model with a stock price of $10.72 per share as of March 30, 2015, an expected term of 0.04 years, and a volatility of 80%. In April 2015, the Company received $5,215 for the full exercise of the warrants. The following summarizes the net consideration paid to Holdings: Consideration Total Cash $ 6,418 Fair value of warrants 22,747 Less cash paid to acquire shares in Inex Bio (1,100 ) Net consideration $ 28,065 The Company recorded compensation expense for the portion of the cash and warrants issued to Holdings that exceeded the fair value of the shares acquired consistent with ASC Topic 718. The Company recorded $22,747 of stock-based compensation and $5,419 of cash compensation to the Company’s chief executive officer and the director as a result of acquiring their interest in Inex Bio.

Notes Payable

Notes Payable	6 Months Ended
	Jun. 30, 2015
Debt Disclosure [Abstract]
Notes Payable	4. Notes Payable 2013 Promissory Note— In June 2013, the Company entered into a Securities Purchase Agreement (the 2013 Securities Purchase Agreement) whereby the Company issued to an institutional investor a $1,000 note payable (the 2013 Promissory Note) plus 1,851 shares of Series B preferred stock for aggregate proceeds of $1,000. The 2013 Promissory Note accrued interest at 5% per annum and was scheduled to mature on June 20, 2014. The 2013 Promissory Note was secured by all of the assets of the Company. The Company allocated the proceeds under the 2013 Securities Purchase Agreement to the 2013 Promissory Note and Series B preferred stock based on their relative fair values, which resulted in $364 and $636 being allocated to the 2013 Promissory Note and Series B preferred stock, respectively. The Company recorded a debt discount of $636, which was being amortized to interest expense over the term of the 2013 Promissory Note using the effective interest method. In April 2014, the Company entered into the 2014 Securities Purchase Agreement at which time the holder of the 2013 Promissory Note agreed to convert the $1,000 principal into 771,458 shares of Series C preferred stock plus a warrant to purchase 192,865 shares of Class A common stock having the same terms as the warrants issued in the 2014 Securities Purchase Agreement. The Company paid accrued interest of $39 in cash. Other Notes and Payables— The 2013 Securities Purchase Agreement was a qualified financing. As a result, certain holders of notes payable and accounts payable totaling $950 (Converting Creditors) converted their outstanding payable balances into Class A common stock at a conversion price of $2.44 per share. The Series A preferred stock holders and Converting Creditors also entered into a shareholder lock up agreement. 2009 Convertible Notes— In 2009, the Company executed a Bridge Loan Agreement to sell and issue $426 of convertible promissory notes (the 2009 Convertible Notes). The 2009 Convertible Notes accrued interest at 15% per annum until maturity on September 30, 2010 (the Maturity Date). After the Maturity Date, the 2009 Convertible Notes accrued interest at 24% per annum. The 2009 Convertible Notes were convertible at the option of the holders into securities issued in the Company’s next financing. The 2009 Convertible Notes were secured by all of the Company’s assets. At December 31, 2013, there was $426 of principal and $396 of accrued interest outstanding on the 2009 Convertible Notes. As discussed below, the 2009 Convertible Notes were exchanged for shares of Class A common stock, and there was no balance outstanding on the 2009 Convertible Notes at December 31, 2014. Each holder of the 2009 Convertible Notes also received a warrant to purchase shares of Class A common stock (2009 Warrants). The 2009 Warrants are exercisable only if and to the extent that the holder subscribed to the next financing for a number of shares equal to 300% of the number of shares issued to the holder in the next financing. The exercise price of the 2009 Warrants initially is the purchase price for the shares in the next financing. However, for up to two years after the date that the Company becomes a public company, the exercise price is adjusted to a price equal to the price of the new equity securities should the Company enter into any new equity transaction whereby the price of the equity in the new transaction is lower than the exercise price of the 2009 Warrants. In conjunction with the 2013 Securities Purchase Agreement, each holder of the 2009 Convertible Notes entered into a consent, amendment and exchange agreement (the Exchange Agreement). The Exchange Agreement (i) modified the Maturity Date to June 20, 2014; (ii) caused each holder to execute a subordination and shareholder lock-up agreement, and; (iii) upon a Mandatory Exchange Financing, automatically exchanged the outstanding principal and accrued interest under the 2009 Convertible Notes and the 2009 Warrants for shares of Class A common stock at an exchange rate of three times the principal amount of the 2009 Convertible Notes divided by the per share price of the Mandatory Exchange Financing. In April 2014, the 2014 Securities Purchase Agreement qualified as a Mandatory Exchange Financing and the $426 principal balance plus $422 accrued interest on the 2009 Convertible Notes and the 2009 Warrants were exchanged for 985,229 shares of the Company’s Class A common stock. In connection with the sale of the 2009 Convertible Notes, the Company used a placement agent. The placement agent received a corporate advisory warrant (the CA Warrant) for common stock equal to 20% of the issued and outstanding common stock of the Company on a fully diluted basis immediately following the final closing of the bridge financing. The CA Warrant had an exercise price of $2.44 per share and was to expire on September 30, 2019. The placement agent also received a warrant for common stock for the number of shares equal to 9% of the number of warrant shares issued to the holders who subscribe to the next financing (the PA Warrant). The initial exercise price of the PA Warrant is equal to the price of the next financing. In conjunction with the 2013 Securities Purchase Agreement, the placement agent agreed to exchange the CA Warrant and PA Warrant into shares of Class A common stock equal to 10% of the shares of fully-diluted stock outstanding immediately following the closing of a Mandatory Exchange Financing less certain exempted issuances. At the 2014 Securities Purchase Agreement closing, the CA Warrant and PA Warrant were exchanged for 3,052,608 shares of the Company’s Class A common stock. The Company also issued to the placement agent 34,715 shares of Class A common stock in exchange for a cash commission. Settlement Agreement— In 2007, the Company entered into a settlement agreement with a former officer of the Company (the Settlement Agreement). The Settlement Agreement included a cash payment to the former officer of $265 payable upon the Company’s receipt of any debt or equity financing. As part of the 2009 Convertible Notes financing, the Settlement Agreement was amended so that the $265 will convert into Class A common stock at a conversion price of $2.44 per share on the second anniversary of Company being a publicly traded company. In March 2015, the Company entered into a Supplemental Agreement and General Release (the Supplemental Agreement) with the former officer related to the Settlement Agreement. As a result, (i) the Company agreed to pay $132 in exchange for retiring the note and (ii) the former officer agreed to exercise a warrant to purchase 32,675 shares of Class A common stock at an exercise price of $2.44 per share. The $133 difference between the carrying value of the note payable and the amount paid to retire the note is reflected in other income on the condensed consolidated statement of operations. Founder Note— As of December 31, 2013, the Company owed a founder of the Company $23 associated with a license agreement and miscellaneous other obligations. In April 2014, the outstanding balance was paid in full. Other Notes and Creditors— As part of the 2009 Convertible Notes financing, certain other note holders and creditors with obligations totaling $194 (Other Creditors) executed agreements either to defer payment for three years or convert the obligations into Class A common stock upon the Company closing a financing of at least $1,200 at a conversion price of $2.44 per share. In conjunction with the 2013 Securities Purchase Agreement, Other Creditors holding $20 of principal plus $29 of accrued interest elected to convert their obligations into 20,205 shares of Class A common stock. Other Creditors holding $50 of principal entered into exchange agreements whereby, upon the Company completing a Mandatory Exchange Financing, the balance plus any accrued interest is automatically exchanged for shares of Class A common stock at an exchange rate of three times the amount owed divided by the per share price of the Mandatory Exchange Financing. At the close of the 2014 Securities Purchase Agreement, the $50 principal plus accrued interest of $50 were exchanged for 230,859 shares of Class A common stock. In April 2014, an Other Creditor with $95 of outstanding principal and interest agreed to sell its note to a third party who agreed to exchange the note for 114,369 shares of Class A common stock. Other Creditors with $29 of outstanding principal plus $13 of accrued interest were repaid in cash in April 2014. Side Agreement Notes— Payables and debt totaling $249 were sold by certain creditors to existing investors (the Side Agreements). In conjunction with the Side Agreements, the Company issued to the investors convertible notes pursuant to an exchange agreement whereby upon the Company completing a Mandatory Exchange Financing, the outstanding balance under the convertible notes are automatically exchanged for shares of Class A common stock at an exchange rate of the amount divided by the per share price of the Mandatory Exchange Financing (the Side Agreement Notes). At the close of the 2014 Securities Purchase Agreement, the $249 balance of the convertible notes was exchanged for 192,341 shares of Class A common stock.

Commitment and Contingencies

Commitment and Contingencies	6 Months Ended
	Jun. 30, 2015
Commitments And Contingencies Disclosure [Abstract]
Commitments and contingencies	5. Commitments and Contingencies Contingencies In March 2009, the Company received a final rejection in one of the Company’s original patent applications pertaining to methods of use claims for NK-92 from the U.S. Patent and Trademark Office (the USPTO). The Company appealed this decision with the USPTO Board of Appeals and, in the fall of 2013, the Board of Appeals reversed the Examiner’s rejection of the claim to certain methods of use with NK-92, but affirmed the Examiner’s rejection of the remaining patent claims. In December 2013, the Company brought an action in the U.S. District Court for the Eastern District of Virginia to review the decision of the USPTO. On September 2, 2015, the U.S. District Court granted the USPTO’s motion for summary judgment. This judgment may impact future revenues. The Company has not yet determined whether it will appeal the decision. Operating Lease The Company leases office space in Cardiff-by-the-Sea, California under a non-cancelable operating lease that expires in August 2016 and leases a research facility in Boston, Massachusetts on a month-to-month basis. Rent expense for the three months ended June 30, 2014 and 2015 was $51 and $87, respectively. Rent expense for the six months ended June 30, 2014 and 2015 was $99 and $158, respectively. In June 2015, the Company entered into a lease agreement for approximately 44,681 square foot facility in San Diego, California for research and development laboratory, related office and other related uses. The term of the lease extends for seven years commencing on August 1, 2016. The base rent is $179 per month with 3% annual increase each anniversary date. In July 2015 the Company entered into a sublease for the building with the current lessee for a term of one year commencing August 1, 2015. There is no fixed rent or operating expenses during the sublease term other than utilities. Collaborative Arrangement A collaborative arrangement is a contractual arrangement that involves a joint operating activity. These arrangements involve two or more parties who are (i) active participants in the activity, and (ii) exposed to significant risks and rewards dependent on the commercial success of the activity. Joint Development and License Agreement— In December 2014, the Company entered into a Joint Development and License Agreement (the Joint Development and License Agreement) with Sorrento Therapeutics, Inc. (Sorrento). Under the Joint Development and License Agreement, the Company and Sorrento agreed to exclusively collaborate on research, development and commercialization with respect to certain technologies and intellectual property rights as may be agreed between the parties for the purpose of jointly developing therapeutic applications of certain effector cell lines. To fund the Company’s joint research and development efforts, Sorrento agreed to make research credit payments to the Company in the aggregate amount of $2,000 payable in December 2015 and 2016, reduced by certain expenses for which the Company is responsible under the agreements. The research credit payments will be paid in the form of full-time employee expense credits by Sorrento to work on behalf of the Company and for the Company’s portion of any development costs and a laboratory credit towards maintaining a laboratory on Sorrento’s premises. For each cell line or product to be developed by the parties pursuant to the Joint Development and License Agreement, one party (the Primary Party), as mutually agreed upon by a designated steering committee comprised of three representatives from each party when a statement of work is agreed to by the parties, will have the right and authority to initiate and control the development, testing, regulatory approval or commercialization of such cell line or joint product, including the right to license and sublicense all applicable intellectual property rights (including joint product rights) with respect thereto. The Primary Party will also bear all costs associated with the development of the applicable cell line or product unless the other party shares in such costs. The ratio of such split between the parties is conditioned on the stage of development of the cell line or product and each party’s contribution towards development costs. Sorrento and the Company each will own an undivided interest in and to all rights, title and interest in and to the joint product rights. The Joint Development and License Agreement expires upon the later of three years or completion of the series of collaborative research and development efforts. In connection with the Joint Development and License Agreement, Sorrento entered into a subscription and investment agreement with the Company under which the Company sold to Sorrento 4,557,537 shares of the Company’s Class A common stock for gross proceeds of $8,000. Subsequently, Sorrento purchased 1,060,789 shares of the Company’s Class A common stock for an additional $2,000 in gross proceeds. There was no additional activity under the Joint Development and License Agreement during the three or six months ended June 30, 2015. Agreements with Affiliates of NantWorks— Our chairman and chief executive officer founded and has a controlling interest in NantWorks, which is a collection of multiple companies in the healthcare and technology space. The Company has entered into arrangements with certain affiliates of NantWorks, as described below, to facilitate the development of new genetically modified NK cells for the Company’s product pipeline. In June 2015, the Company entered into an agreement with NantOmics, LLC (NantOmics) to obtain genomic sequencing and proteomic analysis services, as well as related data management and bioinformatics services, exclusively from NantOmics. The Company is obligated to pay NantOmics a fixed, per sample fee, determined based on the type of services being provided. The agreement has an initial term of five years and renews automatically for successive one year periods, unless terminated earlier. In June 2015, the Company entered into an agreement with NanoCav, LLC (NanoCav) pursuant to which the Company obtained access to NanoCav’s virus-free cell transfection technologies on a non-exclusive basis. Under the agreement, NanoCav will conduct certain, mutually-agreed feasibility studies, on a fee for service basis, to evaluate the use of its cell transfection technologies with the Company’s aNK cells. The agreement has an initial term of five years and renews automatically for successive one year periods, unless terminated earlier. In June 2015, the Company also entered into a supply agreement with NantCell, Inc. (NantCell) pursuant to which the Company has the right to purchase NantCell’s proprietary bioreactors, made according to specifications mutually agreed to with NantCell. The Company also has the right to purchase reagents and consumables associated with such equipment from NantCell. The Company is obligated to make a nonrefundable, upfront payment to NantCell, which is creditable against the Company’s future equipment purchases under the agreement. The agreement has an initial term of five years and renews automatically for successive one year periods unless terminated earlier. There was no activity under these agreements during the three or six months ended June 30, 2015. Royalties and In-licensing Agreements Founder License Agreement— In 2003, the Company entered into a licensing agreement with a founding shareholder of the Company for the exclusive license to the NK-92 cell line and related know-how for payment of certain royalties related to the sales of licensed products (the Founder License Agreement). In 2009 and 2010, the Founder License Agreement was amended for the sale and assignment of the licensed patents to the Company. As consideration for the sale and assignment of the licensed patents and technical information to the Company, the founding shareholder was to receive a one-time cash payment of $75, which was converted to a non-interest bearing note (the Founder Note) (Note 9). In addition, the Company is obligated to (i) pay low single digit percentage royalties of net sales of licensed products for therapeutic and diagnostic use; (ii) issue additional shares of common stock of the Company in conjunction with the closing of a financing of at least $1,000 after the 2013 Securities Purchase Agreement to ensure the founder retains no less than a 7% ownership interest of the total outstanding common shares of the Company on a fully diluted basis; (iii) pay the British Columbia Cancer Agency a low single digit percentage royalty on net sales on aNK cell-based products, a responsibility assumed by the Company for the founding shareholder; and (iv) issue a warrant (Founder Warrant) to purchase up to 123,433 additional shares of Class A common stock at a purchase price of $2.44 per share with a10 year exercise term subject to the completion of five milestones pertaining to granting of a patent, completion of clinical trials and issuance of a commercial biologic license. In 2013, the first milestone, a claim granted for a certain patent application in the United States, was achieved and as a result 37,030 shares underlying the Founder Warrant became exercisable. In March 2014, the Founder License Agreement was amended to (i) provide for payment to the founder of low single digit percentage royalties on net sales of licensed products for therapeutic and diagnostic use and mid-single digit percentage royalties from sublicenses for net sales of licensed products; (ii) exchange warrants held by the founder to purchase up to 156,109 shares of Class A common stock for a fully-vested incentive stock option to purchase up to 740,600 shares of Class A common stock at fair market value on the date of issuance upon the Company closing a private placement of stock or other securities of at least $3,000 (the Mandatory Exchange Financing); and (iii) remove the requirement for the founder to retain not less than a 7% ownership interest of the total outstanding common shares of the Company on a fully diluted basis. As of June 30, 2015, no royalties have been earned or paid. Fox Chase Cancer Center License Agreement— In 2004 and amended in 2008, the Company entered into an exclusive license agreement with Fox Chase Cancer Center (Fox Chase) for the exclusive, worldwide rights to certain patents and know-how pertaining to CD16 receptors bearing NK-92 cell lines. In consideration for this exclusive license granted, the Company agreed to pay Fox Chase (i) low single-digit percentage royalties on net sales of licensed products for therapeutic and diagnostic use; and (ii) mid-twenties percentage royalties on any compensation the Company receives from sublicensees. The Company recorded royalty expense of $26 and $50 for the three months ended June 30, 2015 and 2014 and $51 and $120 for the six months ended June 30, 2015 and 2014, respectively, related to the Fox Chase Cancer Center License Agreement. Royalty expense is included in selling, general and administrative in the condensed consolidated statements of operations. Rush University Medical Center License Agreement— In 2004, the Company entered into a 12-year licensing agreement with Rush University Medical Center for the exclusive rights to license and grant sublicenses of certain intellectual property related to clinical use of NK-92. The Company is required to pay low to mid-single digit percentage royalties on net sales depending upon the various fields of studies and other factors. The Company is required to pay a minimum annual royalty of $25. The Rush University Medical Center License Agreement also provides for payments in the aggregate amount of $2,500 upon the Company achieving various milestones, including upon (i) the completion of Phase II clinical trial associated with the licensed intellectual property; (ii) the approval by the Food and Drug Administration (the FDA) of a new drug application for a licensed product; and (iii) the first year that sales of the licensed product equals or exceeds $250,000. The Rush University Medical Center License Agreement terminates on the 12th anniversary of the first payment of royalties, which occurred in 2006, at which point the license is deemed a perpetual, irrevocable, fully-paid royalty-free, exclusive license, and may be terminated earlier by either party for material breach. During the three months ended June 30, 2015 and 2014, the Company recorded royalty expense of $6 and $6, and during the six months ended June 30, 2015 and 2014, the Company recorded royalty expense of $13 and $38 related to the Rush University Medical Center License Agreement. Royalty expense is included in selling, general and administrative in the condensed consolidated statements of operations. No milestones were met during the six months ended June 30, 2015 or 2014.

Out-Licensing Agreement

Out-Licensing Agreement	6 Months Ended
	Jun. 30, 2015
Licensing Agreement [Abstract]
Out-Licensing Agreement	6. Out-Licensing Agreement Intrexon License Agreement— In February 2010, the Company entered into a 17-year license agreement with Intrexon Corporation (Intrexon) pursuant to which the Company granted to Intrexon a non-exclusive, worldwide, sublicensable license to research and sell products under certain patents relating to modified NK-92 cells that express Intrexon’s proprietary gene sequences for use as a therapeutic and prophylactic agent in humans in specified therapeutic areas. In consideration for the license agreement, Intrexon paid the Company a one-time fee of $350 and will pay the Company the following milestone payments: $50 upon the first IND filing; $100 upon the commencement of the first Phase II clinical trial; $350 upon the commencement of the first Phase III clinical trial; and $500 upon the first commercial sale relating to the licensed products. Intrexon is obligated to pay the Company a low single digit percentage royalty based on net sales of the licensed products by Intrexon and a mid-teen percentage royalty based on revenues received by Intrexon in connection with sublicenses of the licensed products. No milestone payments were due or received in the six months ended June 30, 2015 or 2014.

Spinout of Bank Biologics and C

Spinout of Bank Biologics and Coneksis	6 Months Ended
	Jun. 30, 2015
Discontinued Operations And Disposal Groups [Abstract]
Spinout of Bank Biologics and Coneksis	7. Spinout of Bank Biologics and Coneksis On June 9, 2015, the Company spun out its business related to testing and diagnostic products and services into the entity, Brink Biologics, Inc. (d/b/a Bank Biologics) in exchange for all of the issued and outstanding shares of Bank Biologics which were subsequently distributed by a dividend to our stockholders. Under the spin-out arrangement, the Company transferred to Bank Biologics all of the Company’s existing revenue-earning, non-exclusive license agreements that allow third parties to use the Company’s cell lines and intellectual property for non-clinical laboratory testing. In addition, the Company transferred or licensed to Bank Biologics the Company’s other assets associated with testing and diagnostics products and services. The Company granted to Bank Biologics worldwide, exclusive licenses to the use of certain cell lines limited to the field of in vitro in vivo On June 9, 2015, the Company spun out its business related to veterinary oncology into the entity, Coneksis, Inc. (Coneksis) in exchange for all of the issued and outstanding shares of Coneksis which were subsequently distributed by a dividend to our stockholders. In connection with the spin-out arrangement, the Company granted to Coneksis worldwide, exclusive licenses for use of certain cell lines in the field of veterinary medical research and therapeutics, trademarks, intellectual property, and patents, including the Company’s rights under its license agreement with Fox Chase Cancer Center. As part of the agreement, the Company also has a non-exclusive license to any results and data arising from Coneksis’ use of the Company’s cell lines and intellectual property for the Company’s use for internal research purposes and outside of Coneksis’ field. In consideration for the license grants, Coneksis is obligated to pay the Company a single-digit royalty on amounts received for the sale of licensed products and services, as well as a single-digit percentage share of other revenue received by Coneksis from the grant of sublicenses under the Company’s rights. Coneksis and the Company have the right to terminate the license agreement under certain conditions. Also, as part of the spin-out arrangement, the Company has agreed to provide certain services to Coneksis for a transitional period on a fee-for-service basis. To date, the Company has not provided any services to Coneksis. Had the Company consummated the spin out as of the beginning of the year, there would have been no material impact to the statement of operations for the three months or six months ended June 30, 2015 or the balance sheet as of June 30, 2015. In April 2014, the FASB issued Accounting Standards Update ("ASU") No. 2014-08 - Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity

Stockholders' Equity

Stockholders' Equity	6 Months Ended
	Jun. 30, 2015
Equity [Abstract]
Stockholders' Equity	8. Stockholders’ Equity Conversion — In June 2015, the board of directors and the requisite shareholders approved the conversion of Class A common stock to common stock. Each share of Class A common stock converted into 1.00 share of common stock. Additionally, the number of authorized shares of common stock was increased from 80,000,000 to 100,000,000. Common Stock— In June 2015, the Company sold 3,698,695 shares of common stock in a private placement offering for net proceeds of $70,976 after $28 of issuance costs. Class A Common Stock— In December 2014, the Company issued 4,557,537 shares of Class A common stock at $1.76 per share for gross proceeds of $8,000 in a private placement transaction with Sorrento (Note 5). Subsequently in December 2014, the Company entered into a private placement offering and sold 26,252,262 shares of Class A common stock at $1.89 per share for gross proceeds of $49,495, of which Sorrento purchased 1,060,789 shares for $2,000. Related stock issuance costs totaled $159. In conjunction with the offering, the Company amended its Bylaws to increase the size of the board of directors to nine. In conjunction with the 2013 Securities Purchase Agreement, 389,437 shares of Class A common stock were issued for conversion of certain debt and payables totaling $950, and 406,048 shares were issued in exchange for all outstanding shares of Series A preferred stock. In conjunction with the 2014 Securities Purchase Agreement, the placement agent agreed to exchange $45 of its cash commission for 34,715 shares of Class A common stock. Common Stock Warrants— In 2010, the Company issued, in conjunction with a termination and release agreement, a warrant to purchase 114,822 shares of Class A common stock. The warrant was initially exercisable at $2.44 per share and is currently exercisable at $1.76 per share. The warrant expires in February 2020. The warrant includes a provision that for a period through two years after a reverse merger, the exercise price of the warrant is protected against down-round financing unless 66.67% of shareholders consent to the new transaction. Pursuant to ASC Subtopic 815-15 and ASC Subtopic 815-40, the fair value of the warrant of $439 was recorded as a derivative liability on the issuance date. The fair value of the warrant was estimated at the issuance date and is revalued at each reporting period, using a Monte Carlo simulation. At December 31, 2014 and April 30, 2015 , the date of exercise , the Company recorded a derivative liability of approximately $177 and $1,543, respectively. The change in fair value of the derivative liability is included in other income (expense) in the statements of operations. In April 2015, the warrant was exercised. In March 2015, the board of directors approved the issuance of a stock option and a warrant to purchase Class A common stock to an officer of the Company (Note 9). In connection with its acquisition of Inex Bio in March 2015, the Company issued warrants to purchase 3,202,593 shares of Class A common stock with an exercise price of $2.00 per share (Note 3). In April 2015, the Company received $6,400 for the full exercise of the warrants. On June 18, 2015, the Company repurchased 249,952 shares of common stock from an employee at $19.20 per share for $4,798.

Stock-Based Compensation

Stock-Based Compensation	6 Months Ended
	Jun. 30, 2015
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Stock-Based Compensation	9. Stock-Based Compensation 2004 Stock Option Plan— In April 2004, the Company adopted the 2004 Stock Option Plan (the 2004 Plan) under which 81,695 shares of common stock were reserved for issuance under the 2004 Plan. The 2004 Plan provides for the granting of stock options to employees, directors and consultants of the Company. Options granted under the 2004 Plan may be either incentive stock options (ISOs) or nonqualified stock options (NSOs). NSOs may be granted to the Company employees and consultants. No further shares are available for grant under the 2004 Plan. 2014 Equity Incentive Plan— In March 2014, the Company’s board of directors and stockholders approved the 2014 Equity Incentive Plan (2014 Plan) under which 11,109,000 shares of Class A common stock are reserved for the granting of incentive stock options, nonstatutory stock options, stock appreciation rights, restricted stock, restricted stock units and performance awards to employees, directors and consultants. Recipients of stock awards are eligible to purchase shares of the Company’s common stock at an exercise price equal to no less than the estimated fair market value of such stock on the date of grant. The maximum term of awards granted under the 2014 Plan is ten years. Stock awards are generally not exercisable prior to the applicable vesting date, unless otherwise accelerated under the terms of the applicable stock plan agreement. Unvested shares of the Company’s common stock issued in connection with an early exercise allowed by the Company may be repurchased by the Company upon termination of the optionee’s service with the Company. Stock-based Awards to an Officer— In March 2015, the Company granted to an officer an option to purchase 1,851,500 shares of the Company’s Class A common stock at an exercise price of $2.20 per share. The option vests in equal monthly installments over a period of four years from the date of grant. In March 2015, the board of directors approved the issuance of a warrant to purchase Class A common stock to an officer of the Company. The warrant has a four year term and an exercise price of $2.00 per share. The maximum number of shares underlying the warrant is 17,589,250 of which 7,406,000 vest over a 40-month service period beginning on April 1, 2015 and the remaining 10,183,250 vest based on the achievement of various milestones. For the three months ended June 30, 2015, a total of 8,887,200 were vested. The following table summarizes stock option transactions under the 2014 Plan for the six months ended June 30, 2015: Number of Shares Weighted- Average Exercise Aggregate Intrinsic Value Weighted- Average Remaining Contractual (in years) Outstanding at December 31, 2014 5,137,914 Options granted 4,258,449 $ 2.08 Options forfeited — Options exercised (949,154 ) $ 0.81 Outstanding at June 30, 2015 8,447,209 $ 1.48 $ 149,663 8.11 Vested and Exercisable at June 30, 2015 2,452,979 $ 0.83 $ 45,045 8.95 The following table provides a summary of options outstanding and vested as of June 30, 2015: Exercise Prices Number Outstanding Weighted- Average Life (in Years) Number Exercisable Weighted- Average Life (in Years) $0.22 1,450,349 8.71 825,468 8.71 $0.42 1,122,859 9.40 869,435 9.40 $1.76 1,615,552 9.46 150,553 9.46 $2.00 2,406,949 9.62 491,804 9.62 $2.20 1,851,500 3.73 115,719 3.73 8,447,209 8.11 2,452,979 8.95 The aggregate intrinsic value of stock options exercised during the three months ended June 30, 2015 was $14,818. The Company recorded total employee stock-based compensation expense for stock options under the 2014 Plan of $2,521 and $29 for the three months ended June 30, 2015 and 2014, and $3,609 and $164 for the six months ended June 30, 2015 and 2014. The total unrecognized compensation cost related to non-vested stock options as of June 30, 2015 was $27,732, which is expected to be recognized over a weighted-average period of 2.69 years. The Company records equity instruments issued to non-employees as expense at the fair value over the related service period as determined in accordance with the authoritative guidance and periodically revalues the equity instruments as they vest. There were no stock options granted to non-employees during the three months ended June 30, 2015 and 2014. As of June 30, 2015, there were 354,870 non-employee options outstanding of which 73,288 were vested. During the three months ended June 30, 2015 and 2014, the Company recorded stock-based compensation expense related to non-employee consultants of $1,602 and $3, and $2,290 and $3 for the six months ended June 30, 2015 and 2014. The Company uses a Black-Scholes option-pricing model to determine the fair value of stock-based compensation under ASC Topic 718, Stock Compensation Six Months Ended June 30, 2015 2014 Employee Grants Non-Employee Grants Employee Grants Non-Employee Grants Expected term (years) 4.00-5.52 10.00 5.00-5.52 10.00 Risk-free interest rate 1.45%-1.79% 2.14% 1.58%-1.89% 2.70% Expected volatility 80% 80% 91% 91% Dividend yield 0% 0% 0% 0% Weighted-average grant date fair value $6.15 $5.19 $0.16 $0.19 The assumed dividend yield was based on the Company’s expectation of not paying dividends in the foreseeable future. The estimated volatility is based on a weighted-average calculation of a peer group of comparable companies whose share prices are publicly available. The risk-free interest rate assumption was based on the U.S. Treasury’s rates for U.S. Treasury zero-coupon bonds with maturities similar to those of the expected term of the award being valued. The weighted-average expected life of options was estimated using the average of the contractual term and the weighted-average vesting term of the options. The following table presents all stock-based compensation as included in the Company’s condensed consolidated statement of operations: Three Months Ended June 30, Six Months Ended June 30, 2015 2014 2015 2014 Stock-based compensation expense: Warrants for Class A common stock to an officer and a director related to Inex Bio, Inc. acquisition (Note 3) $ — $ — $ 22,747 $ — Warrants for Class A common stock to an officer 75,918 — 75,918 Employee stock options 2,521 29 3,609 164 Non-employee stock options 1,602 3 2,290 3 $ 80,041 $ 32 $ 104,564 $ 167 Stock-based compensation expense in operating expenses: Research and development $ 587 $ — $ 776 $ — Selling, general and administrative 79,454 32 103,788 167 $ 80,041 $ 32 $ 104,564 $ 167

Fair Value Measurement

Fair Value Measurement	6 Months Ended
	Jun. 30, 2015
Fair Value Disclosures [Abstract]
Fair Value Measurement	10. Fair Value Measurement The carrying amounts of certain financial instruments, including cash and cash equivalents, accounts receivable, prepaid expenses, accounts payable, accrued expenses and notes payable approximate their respective fair values due to the short-term nature of such instruments. Assets and Liabilities Measured at Fair Value on a Recurring Basis The Company evaluates its financial assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level in which to classify them for each reporting period. This determination requires significant judgments to be made. The following table summarizes the conclusions reached: Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Warrant derivative liability at December 31, 2014 $ — $ — $ 177 Warrant derivative liability at June 30, 2015 $ — $ — $ — The Company used Level 3 inputs for its valuation methodology for the warrant derivative liability. The estimated fair value was determined using a Monte Carlo option pricing model based on various assumptions. The Company’s warrant derivative liability is adjusted to reflect estimated fair value at each reporting period, with any decrease or increase in the estimated fair value recorded in other income or expense as an adjustment to the fair value of warrant derivative liability. The assumptions used in valuing these warrants are presented in the table below. April 30, 2015 (settlement date) December 31, 2014 Expected dividend yield 0% 0% Expected volatility 80.0% 79.5% Risk-free interest rate 1.43% 1.67% Marketability discount 10.0% 10.0% In addition, as of the valuation dates, management assessed the probabilities of future financings assumptions in the Monte Carlo valuation models. The Company also applied a discount for lack of marketability to the valuation of the warrant derivative liability based on such trading restrictions due to the shares not being registered. Activity for the warrant derivative liability measured at fair value using significant unobservable inputs (Level 3) is presented in the table below: Warrant Derivative Liability Balance January 1, 2015 $ 177 Adjustment to estimated fair value 1,366 Warrant exercised (1,543 ) Balance at June 30, 2015 $ —

Subsequent Events

Subsequent Events	6 Months Ended
	Jun. 30, 2015
Subsequent Events [Abstract]
Subsequent Events	11. Subsequent Events Sale of common stock— On July 8, 2015, the Company sold 364,636 shares of common stock in a private placement offering for gross proceeds of $7,000. On July 31, 2015, the Company closed its initial public offering and sold 9,531,200 shares of common stock for proceeds of $225,486 after underwriters’ discounts and commissions, but before offering expenses of approximately $3,000. In addition, the Company completed a separate private placement concurrent with the completion of the initial public offering and sold 680,000 shares of common stock for proceeds of $17,000. 2015 Equity Incentive Plan— In July 2015, the Company’s board of directors adopted the 2015 Equity Incentive Plan (the 2015 Plan). The 2015 Plan permits the grant of incentive stock options, within the meaning of Section 422 of the Code, to the Company’s employees and for the grant of nonstatutory stock options, restricted stock, restricted stock units, stock appreciation rights, performance units and performance shares to the Company’s employees, directors and consultants. A total of 3,500,000 shares were reserved for issuance pursuant to the 2015 Plan. In addition, the shares reserved for issuance under the 2015 Plan also included shares reserved but not issued under the 2014 Equity Incentive Plan, and shares subject to stock options or similar awards granted under the 2014 Equity Incentive Plan that expire or terminate without having been exercised in full and shares issued pursuant to awards granted under the 2014 Equity Incentive Plan that are forfeited to or repurchased by the Company (provided that the maximum number of shares that may be added to the 2015 Plan pursuant to this provision is 9,197,066 shares). Amended Employment Agreement— In July 2015, the Company amended the employment agreement with its Chief Executive Officer. The amended employment agreement provides that, upon the initial public offering of the Company’s common stock, the officer will be eligible to receive awards pursuant to the terms and conditions of the Company’s 2015 Equity Incentive Plan, consisting of options to purchase 900,000 shares of common stock with an exercise price equal to the initial public offering price and grants of 600,000 restricted stock units representing the right to receive one share of common stock for each restricted stock unit that vests. Under the terms of the amended employment agreement, 50% of these awards vest upon grant, and the remaining 50% vest upon the first anniversary of the Company’s initial public offering, subject to continued employment through the applicable vesting dates. The amended employment agreement provides that, commencing as of the first calendar year following the grant of the awards, or in 2015 if the initial public offering does not occur, the executives will be eligible to receive additional annual equity grants as determined by the board of directors or its compensation committee. Forward Stock Split— On July 10, 2015, the Company amended its amended and restated certificate of incorporation effecting a 1.8515-for-1 forward stock split of its common stock. The forward stock split did not cause an adjustment to the par value or the authorized shares of the common stock or preferred stock. As a result of the forward stock split, the Company also adjusted the share and per-share amounts under its 2014 Equity Incentive Stock Plan and common stock warrant agreements with third parties. No fractional shares were issued in connection with the forward stock split. All disclosure of common shares and per common share data in the accompanying financial statements and related notes have been adjusted retroactively to reflect the forward stock split for all periods presented. Amended and Restated Certificate of Incorporation— On July 31, 2015 the Company amended its Certificate of Incorporation to increase the number of authorized shares of common stock from 100,000,000 to 500,000,000. Issuance of options and restricted stock units to Officers— In accordance with their employment agreements, the Company granted to its Chief Executive Officer and Chief Operating Officer upon the initial public offering a total of 1,455,450 options to purchase common stock with an exercise price of $25.00 per share and 970,300 restricted stock units representing the right to receive one share of the Company’s common stock for each restricted stock unit that becomes vested. The options and restricted stock units vested 50% at grant and the remaining 50% will vest upon the first anniversary of the initial public offering.

Summary of Significant Accoun20

Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2015
Accounting Policies [Abstract]
Principles of Consolidation	Principles of Consolidation The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary, Inex Bio, Inc. (Note 3), and have been prepared in accordance with accounting principles generally accepted in the United States of America. All intercompany accounts and transactions have been eliminated in consolidation.
Liquidity	Liquidity As of June 30, 2015, the Company had an accumulated deficit of approximately $130,004. The Company also had negative cash flow from operations of approximately $10,042 during the six months ended June 30, 2015. The Company expects that it will likely need additional capital to further fund development of, and seek regulatory approvals for, its product candidates, and begin to commercialize any approved products. The Company is currently focused primarily on the development of immunotherapeutic treatments for cancers and debilitating viral infections using targeted cancer killing cell lines, and believes such activities will result in the Company’s continued incurrence of significant research and development and other expenses related to those programs. If the clinical trials for any of the Company’s product candidates fail or produce unsuccessful results and those product candidates do not gain regulatory approval, or if any of the Company’s product candidates, if approved, fails to achieve market acceptance, the Company may never become profitable. Even if the Company achieves profitability in the future, it may not be able to sustain profitability in subsequent periods. The Company intends to cover its future operating expenses through cash and cash equivalents on hand and through a combination of equity offerings, debt financings, government or other third-party funding, marketing and distribution arrangements and other collaborations, strategic alliances and licensing arrangements. Additional financing may not be available to the Company when needed and, if available, financing may not be obtained on terms favorable to the Company or its stockholders. While the Company expects its existing cash and cash equivalents will enable it to fund operations and capital expenditure requirements for at least the next twelve months, it may not have sufficient funds to reach commercialization. Failure to obtain adequate financing when needed may require the Company to delay, reduce, limit or terminate some or all of its development programs or future commercialization efforts or grant rights to develop and market product candidates that the Company might otherwise prefer to develop and market itself which could adversely affect the Company’s ability to operate as a going concern. If the Company raises additional funds from the issuance of equity securities, substantial dilution to existing stockholders may result. If the Company raises additional funds by incurring debt financing, the terms of the debt may involve significant cash payment obligations as well as covenants and specific financial ratios that may restrict the Company’s ability to operate its business.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. On an ongoing basis, the Company evaluates its estimates, including those related to the recoverability of patent costs included in intangible assets, valuation of warrants, stock-based compensation, the valuation allowance for deferred tax assets, allowance for doubtful accounts and business combinations. The Company bases its estimates on historical experience and on various other market-specific and relevant assumptions that it believes to be reasonable under the circumstances. Actual results could differ from those estimates.
Risks and Uncertainties	Risks and Uncertainties Concentration of Credit Risk Financial instruments, which potentially expose the Company to concentrations of credit risk, consist principally of cash balances on deposit with a bank, which exceed insured limits, and accounts receivable. The Company performs ongoing credit evaluations of customers’ financial condition, and the Company does not require collateral. There were five and seven customers that comprised the entire accounts receivable balance at June 30, 2015 and December 31, 2014, respectively. At June 30, 2015 and December 31, 2014, four and six customers, respectively, each had accounts receivable balances in excess of 10% of total accounts receivable. For the three months ended June 30, 2015, the Company derived revenue of $11 from one customer, representing 12% of the Company’s total revenue, compared to revenue of $19 from one customer, representing 15% of the Company’s total revenue for the three months ended June 30, 2014. For the six months ended June 30, 2015, the Company derived revenue of $27 from one customer, representing 13% of the Company’s total revenue, compared to revenue of $160 from one customer, representing 39% of the Company’s total revenue for the six months ended June 30, 2014. USPTO Proceeding In March 2009, the Company received a final rejection in one of the Company’s original patent applications pertaining to methods of use claims for NK-92 from the U.S. Patent and Trademark Office (the USPTO). The Company appealed this decision with the USPTO Board of Appeals and, in the fall of 2013, the Board of Appeals reversed the Examiner’s rejection of the claim to certain methods of use with NK-92, but affirmed the Examiner’s rejection of the remaining patent claims. In December 2013, the Company brought an action in the U.S. District Court for the Eastern District of Virginia to review the decision of the USPTO. On September 2, 2015, the U.S. District Court granted the USPTO’s motion for summary judgment. The Company has not yet determined whether it will appeal the decision.
Intangible Assets	Intangible Assets Intangible assets consist of costs incurred in connection with patent applications (principally legal fees), patent purchases, trademarks related to the Company’s aNK cells and technology acquired in the asset purchase of Inex Bio. The Company calculates amortization expense for its patents and acquired technology using the straight-line method over the estimated useful lives, generally 4-15 years. Other intangibles, consisting of trademarks and copyrights, are considered to have indefinite lives and are not amortized but reviewed for impairment annually, or sooner under certain circumstances. The Company has no historical data to support a probable future economic benefit for patent applications, filing and prosecution costs other than for the Company’s aNK cells. Therefore, these patent-related costs are expensed as incurred and are included in selling, general and administrative in the statements of operations. The Company capitalizes patent application costs for those patents that are generating revenue currently. Should the Company experience a legal cost to defend a patent in the future, that cost would be capitalized only when it is part of the cost of retaining and obtaining the future economic benefit of the patent. Costs related to an unsuccessful outcome would be expensed.
Fair Value of Financial Instruments	Fair Value of Financial Instruments The accounting standard for fair value measurements provides a framework for measuring fair value and requires disclosures regarding fair value measurements. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date, based on the Company’s principal or, in absence of a principal, most advantageous market for the specific asset or liability. The Company uses a three-tier fair value hierarchy to classify and disclose all assets and liabilities measured at fair value on a recurring basis, as well as assets and liabilities measured at fair value on a non-recurring basis, in periods subsequent to their initial measurement. The hierarchy requires the Company to use observable inputs when available, and to minimize the use of unobservable inputs, when determining fair value. The three tiers are defined as follows: · Level 1—Observable inputs that reflect quoted market prices (unadjusted) for identical assets or liabilities in active markets; · Level 2—Observable inputs other than quoted prices in active markets that are observable either directly or indirectly in the marketplace for identical or similar assets and liabilities; and · Level 3—Unobservable inputs that are supported by little or no market data, which require the Company to develop its own assumptions.
Revenue Recognition and Deferred Revenue	Revenue Recognition and Deferred Revenue The Company derives substantially all of its revenue from non-exclusive license agreements with numerous pharmaceutical and biotechnology companies granting them the right to use the Company’s cell lines and intellectual property for non-clinical use. These license agreements generally include upfront fees and annual research license fees for such use, as well as commercial fees for sales of the licensees’ products developed or manufactured using the Company’s intellectual property and cell lines. The Company’s license agreements also may include milestone payments, although to date, the Company has not generated any revenue from milestone payments. The Company recognizes revenue when (i) persuasive evidence of an arrangement exists; (ii) delivery of the products and/or services has occurred; (iii) the fees are fixed or determinable; and (iv) collectibility is reasonably assured. When entering into an arrangement, the Company first determines whether the arrangement includes multiple deliverables and is subject to accounting guidance in Accounting Standards Codification (ASC) Subtopic 605-25, Multiple-Element Arrangements An element qualifies as a separate unit of accounting when the delivered element has standalone value to the customer. The Company’s agreements do not include a general right of return relative to delivered elements. Any delivered elements that do not qualify as separate units of accounting are combined with other undelivered elements within the arrangement as a single unit of accounting. If the arrangement constitutes a single combined unit of accounting, the Company determines the revenue recognition method for the combined unit of accounting and recognizes the revenue over the period from inception through the date the last deliverable within the single unit of accounting is delivered. License rights and non-contingent deliverables, such as knowledge transfer, do not have standalone value as they are not sold separately and they cannot be resold and, consequently are considered a single unit of accounting. Therefore, license revenue in the form of upfront payments is deferred and recognized over the applicable relationship period, which historically has been the estimated period of the Company’s substantive performance obligations or the period the rights granted are in effect. The Company recognizes a milestone payment when earned if it is substantive and the Company has no ongoing performance obligations related to the milestone. A milestone payment is considered substantive if it 1) is commensurate with either the Company’s performance to achieve the milestone or the enhanced value of the delivered item as a result of a specific outcome resulting from the Company’s performance to achieve the milestone; 2) relates solely to past performance; and 3) is reasonable relative to all of the deliverables and payment terms, including other potential milestone consideration, within the arrangement. The Company records any amounts received prior to satisfying the revenue recognition criteria as deferred revenue in the accompanying balance sheets.
Stock-Based Compensation	Stock-Based Compensation The Company measures and recognizes compensation expense for all stock-based payment awards made to employees, officers and directors based on the estimated fair values of the awards as of the grant date. The Company records the value of the portion of the award that is ultimately expected to vest as expense over the requisite service period. The Company also accounts for equity instruments issued to non-employees using a fair value approach under ASC Subtopic 505-50, Equity-Based Payments to Non-Employees. The Company values equity instruments and stock options granted using the Black-Scholes option-pricing model. The value of non-employee stock-based compensation is subject to periodic adjustments as the underlying equity instruments vest and is recognized as an expense over the term of the related financing or the period over which services are received.
Basic and Diluted Net Loss Per Share of Common Stock	Basic and Diluted Net Loss per Share of Common Stock Basic net loss per share is calculated by dividing the net loss by the weighted-average number of common shares outstanding for the period. Diluted loss per share is computed similarly to basic loss per share except that the denominator is increased to include the number of additional shares that would have been outstanding if the potential common shares had been issued and if the additional common shares were dilutive. For all periods presented, potentially dilutive securities are excluded from the computation of fully diluted loss per share as their effect is anti-dilutive. The following table details those securities which have been excluded from the computation of potentially dilutive securities: Three and Six Months Ended June 30, 2015 2014 Series B convertible preferred stock — 8,888,597 Series C convertible preferred stock — 5,789,699 Class B common shares not exercised — 5,735,704 Outstanding options 8,447,209 3,425,769 Outstanding warrants 18,417,078 2,052,408 Total 26,864,287 25,892,177 Amounts in the table above reflect the common stock equivalents of the noted instruments.
Comprehensive Loss	Comprehensive Loss The Company has no items of comprehensive income or loss other than net loss.
Segment and Geographic Information	Segment and Geographic Information Operating segments are defined as components of an enterprise (business activity from which it earns revenue and incurs expenses) for which discrete financial information is available and regularly reviewed by the chief operating decision maker in deciding how to allocate resources and in assessing performance. The Company’s chief operating decision maker (CODM) is its Chief Executive Officer. The Company views its operations and manages its business as a single operating and reporting segment

Summary of Significant Accoun21

Summary of Significant Accounting Policies (Tables)	6 Months Ended
	Jun. 30, 2015
Accounting Policies [Abstract]
Securities Excluded from the Computation of Potentially Dilutive Securities	The following table details those securities which have been excluded from the computation of potentially dilutive securities: Three and Six Months Ended June 30, 2015 2014 Series B convertible preferred stock — 8,888,597 Series C convertible preferred stock — 5,789,699 Class B common shares not exercised — 5,735,704 Outstanding options 8,447,209 3,425,769 Outstanding warrants 18,417,078 2,052,408 Total 26,864,287 25,892,177

Investment In Inex Bio, Inc (Ta

Investment In Inex Bio, Inc (Tables)	6 Months Ended
	Jun. 30, 2015
Summary of Purchase Price Paid to Inex Bio	The following summarizes the net consideration paid to Holdings: Consideration Total Cash $ 6,418 Fair value of warrants 22,747 Less cash paid to acquire shares in Inex Bio (1,100 ) Net consideration $ 28,065
Summary of Assets and Liabilities Assumed	The following table summarizes the assets acquired and liabilities assumed: March 31, 2015 Cash $ 763 Intangible assets—reacquire rights of Company technology 7,199 Other assets 12 Investment in Inex Bio (221 ) Accounts payable (1 ) Total assets acquired and liabilities assumed $ 7,752
Inex Bio Inc
Summary of Purchase Price Paid to Inex Bio	The purchase price paid to acquire Inex Bio from the other owners is as follows: Consideration Total Cash paid by Inex Bio Holdings Inc. $ 1,100 Cash paid by Company 1,482 Fair value of warrants 5,170 Aggregate purchase price $ 7,752

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	6 Months Ended
	Jun. 30, 2015
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Summarizes Stock Option Transactions Under Equity Intensive Plan	The following table summarizes stock option transactions under the 2014 Plan for the six months ended June 30, 2015: Number of Shares Weighted- Average Exercise Aggregate Intrinsic Value Weighted- Average Remaining Contractual (in years) Outstanding at December 31, 2014 5,137,914 Options granted 4,258,449 $ 2.08 Options forfeited — Options exercised (949,154 ) $ 0.81 Outstanding at June 30, 2015 8,447,209 $ 1.48 $ 149,663 8.11 Vested and Exercisable at June 30, 2015 2,452,979 $ 0.83 $ 45,045 8.95
Summary of Options Outstanding and Vested	The following table provides a summary of options outstanding and vested as of June 30, 2015: Exercise Prices Number Outstanding Weighted- Average Life (in Years) Number Exercisable Weighted- Average Life (in Years) $0.22 1,450,349 8.71 825,468 8.71 $0.42 1,122,859 9.40 869,435 9.40 $1.76 1,615,552 9.46 150,553 9.46 $2.00 2,406,949 9.62 491,804 9.62 $2.20 1,851,500 3.73 115,719 3.73 8,447,209 8.11 2,452,979 8.95
Weighted Average Assumptions of Fair Value of Stock Options Under Black-Scholes Option Pricing Model	The Company uses a Black-Scholes option-pricing model to determine the fair value of stock-based compensation under ASC Topic 718, Stock Compensation Six Months Ended June 30, 2015 2014 Employee Grants Non-Employee Grants Employee Grants Non-Employee Grants Expected term (years) 4.00-5.52 10.00 5.00-5.52 10.00 Risk-free interest rate 1.45%-1.79% 2.14% 1.58%-1.89% 2.70% Expected volatility 80% 80% 91% 91% Dividend yield 0% 0% 0% 0% Weighted-average grant date fair value $6.15 $5.19 $0.16 $0.19
Stock Based Compensation Expenses Included in Operations Statement	The following table presents all stock-based compensation as included in the Company’s condensed consolidated statement of operations: Three Months Ended June 30, Six Months Ended June 30, 2015 2014 2015 2014 Stock-based compensation expense: Warrants for Class A common stock to an officer and a director related to Inex Bio, Inc. acquisition (Note 3) $ — $ — $ 22,747 $ — Warrants for Class A common stock to an officer 75,918 — 75,918 Employee stock options 2,521 29 3,609 164 Non-employee stock options 1,602 3 2,290 3 $ 80,041 $ 32 $ 104,564 $ 167 Stock-based compensation expense in operating expenses: Research and development $ 587 $ — $ 776 $ — Selling, general and administrative 79,454 32 103,788 167 $ 80,041 $ 32 $ 104,564 $ 167

Fair Value Measurement (Tables)

Fair Value Measurement (Tables)	6 Months Ended
	Jun. 30, 2015
Fair Value Disclosures [Abstract]
Schedule of Conclusion Reached	The following table summarizes the conclusions reached: Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Warrant derivative liability at December 31, 2014 $ — $ — $ 177 Warrant derivative liability at June 30, 2015 $ — $ — $ —
Schedule of Assumptions Used For Valuing The Warrants	The assumptions used in valuing these warrants are presented in the table below. April 30, 2015 (settlement date) December 31, 2014 Expected dividend yield 0% 0% Expected volatility 80.0% 79.5% Risk-free interest rate 1.43% 1.67% Marketability discount 10.0% 10.0%
Schedule of Warrant Liability Measured At Fair Value Using Significant Unobservable Input (Level 3)	Activity for the warrant derivative liability measured at fair value using significant unobservable inputs (Level 3) is presented in the table below: Warrant Derivative Liability Balance January 1, 2015 $ 177 Adjustment to estimated fair value 1,366 Warrant exercised (1,543 ) Balance at June 30, 2015 $ —

Description of Business and B25

Description of Business and Basis of Presentation - Additional Information (Details) $ in Thousands	Jul. 10, 2015	Mar. 31, 2014	Jun. 30, 2015USD ($)	Jun. 30, 2014USD ($)	Dec. 31, 2014USD ($)
Description Of Business And Basis Of Presentation [Line Items]
Forward stock split of its outstanding common stock			1.8515
Accumulated deficit			$ 130,004		$ 12,741
Net cash used in operating activities			$ 10,042	$ 2,093
Subsequent Event
Description Of Business And Basis Of Presentation [Line Items]
Forward stock split of its outstanding common stock	1.8515
Common Stock | Subsequent Event
Description Of Business And Basis Of Presentation [Line Items]
Forward stock split of its outstanding common stock	1.8515
Series B Preferred Stock
Description Of Business And Basis Of Presentation [Line Items]
Common stock, conversion basis			In March 2014, the Company entered into a definitive merger and share exchange agreement pursuant to which the Company redomesticated from the State of Illinois to the State of Delaware and the Illinois Company ceased to exist (the Redomestication). In connection with the Redomestication, the holders of Class A and Class B common stock received one share of Class A and Class B common stock of the Delaware Company, respectively, in exchange for fifteen shares of the Illinois Company. The holders of Series B preferred stock received one share of Series B preferred stock of the Delaware Company in exchange for one share of the Illinois Company. The holders of any options, warrants or other securities are subject to adjustment based on the ratio of one for fifteen. All share numbers and per share prices in the accompanying financial statements have been adjusted to reflect the 1 for 15 exchange.
Forward stock split of its outstanding common stock		0.067

Summary of Significant Accoun26

Summary of Significant Accounting Policies - Additional Information (Details) $ in Thousands	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2015USD ($)	Jun. 30, 2014USD ($)	Jun. 30, 2015USD ($)Customer	Jun. 30, 2014USD ($)	Dec. 31, 2014Customer
Accounting Policies [Line Items]
Revenue	$ 91	$ 124	$ 211	$ 410
Minimum
Accounting Policies [Line Items]
Estimated useful lives of intangible assets			4 years
Maximum
Accounting Policies [Line Items]
Estimated useful lives of intangible assets			15 years
Accounts Receivable
Accounting Policies [Line Items]
Number of customers | Customer			4		6
Concentration of Credit Risk | Accounts Receivable
Accounting Policies [Line Items]
Percentage of revenue			10.00%		10.00%
Customer Concentration Risk | Sales
Accounting Policies [Line Items]
Percentage of revenue	12.00%	15.00%	13.00%	39.00%
Revenue	$ 11	$ 19	$ 27	$ 160

Summary of Significant Accoun27

Summary of Significant Accounting Policies - Securities Excluded from the Computation of Potentially Dilutive Securities (Details) - shares	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	26,864,287	25,892,177	26,864,287	25,892,177
Series B Convertible Preferred Stock
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount		8,888,597		8,888,597
Series C Convertible Preferred Stock
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount		5,789,699		5,789,699
Class B Common Shares Not Exercised
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount		5,735,704		5,735,704
Outstanding Options
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	8,447,209	3,425,769	8,447,209	3,425,769
Outstanding Warrants
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	18,417,078	2,052,408	18,417,078	2,052,408

Investment in Inex Bio, Inc - A

Investment in Inex Bio, Inc - Additional Information (Detail) - USD ($)	Mar. 30, 2015	Apr. 30, 2015	May. 31, 2012	Apr. 30, 2012	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014	Mar. 31, 2014
Business Acquisition [Line Items]
Number of shares acquired during period			57,000
Stock issued during period, value, acquisitions			$ 249,000
Outstanding shares acquired, percentage			22.20%
Percentage of fully diluted shares acquired			17.40%
Percentage of equity owned by partners									7.00%
Proceeds from exercise of warrants							$ 7,134,000
Stock-based compensation expense					$ 80,041,000	$ 32,000	$ 104,564,000	$ 167,000
Common Class A
Business Acquisition [Line Items]
Stock price of warrants					$ 2.44		$ 2.44
Inex Bio Holdings
Business Acquisition [Line Items]
Percentage of equity owned by partners					50.00%		50.00%
Payments to acquire business							$ 6,418,000
Stock price of warrants	$ 10.72
Term of warrants after closing date of the purchase agreement	15 days
Expected volatility rate	80.00%
Stock-based compensation expense							22,747,000
Cash based compensation							$ 5,419,000
Inex Bio Holdings | Common Class A
Business Acquisition [Line Items]
Warrants issued to acquire shares							2,609,520
Common stock exercise price					$ 2		$ 2
Proceeds from exercise of warrants		$ 5,215,000
Eragon Ventures, LLC
Business Acquisition [Line Items]
Number of shares acquired during period							220,000
Percentage of equity owned by partners					50.00%		50.00%
Percentage shares acquired					67.30%		67.30%
Payments to acquire business							$ 1,100,000
Other Owner Of Inex Bio Inc
Business Acquisition [Line Items]
Payments to acquire business							$ 1,482,000
Stock price of warrants	$ 10.72
Term of warrants after closing date of the purchase agreement	15 days
Expected volatility rate	80.00%
Reacquired rights period							4 years
Other Owner Of Inex Bio Inc | Common Class A
Business Acquisition [Line Items]
Warrants issued to acquire shares							593,072
Common stock exercise price					$ 2		$ 2
Proceeds from exercise of warrants		$ 1,185,000
Inex license agreement
Business Acquisition [Line Items]
Milestone payment amount							$ 0	$ 0
Percentage of royalty on net sales				5.00%
Inex license agreement | Up front fee
Business Acquisition [Line Items]
License fees received				$ 300,000
Inex license agreement | Maximum
Business Acquisition [Line Items]
Milestone payment amount				$ 775,000

Investment in Inex Bio, Inc - S

Investment in Inex Bio, Inc - Summary of Purchase Price Paid to Inex Bio (Detail) - Other Owner Of Inex Bio Inc $ in Thousands	6 Months Ended
	Jun. 30, 2015USD ($)
Business Acquisition [Line Items]
Cash paid by Inex Bio Holdings Inc.	$ 1,100
Payments to acquire business	1,482
Fair value of warrants	5,170
Aggregate purchase price	$ 7,752

Investment in Inex Bio, Inc -30

Investment in Inex Bio, Inc - Summary of Assets and Liabilities Assumed (Detail) - Other Owner Of Inex Bio Inc $ in Thousands	Mar. 31, 2015USD ($)
Business Acquisition [Line Items]
Cash	$ 763
Intangible assets—reacquire rights of Company technology	7,199
Other assets	12
Investment in Inex Bio	(221)
Accounts payable	(1)
Total assets acquired and liabilities assumed	$ 7,752

Investment in Inex Bio, Inc -31

Investment in Inex Bio, Inc - Summary of Net Consideration Paid to Holdings (Detail) - Inex Bio Holdings $ in Thousands	6 Months Ended
	Jun. 30, 2015USD ($)
Business Acquisition [Line Items]
Payments to acquire business	$ 6,418
Fair value of warrants	22,747
Less cash paid to acquire shares in Inex Bio	(1,100)
Aggregate purchase price	$ 28,065

Notes Payable - Additional Info

Notes Payable - Additional Information (Detail) - USD ($)	Jun. 30, 2013	Mar. 31, 2015	Apr. 30, 2014	Jun. 30, 2015	Dec. 31, 2014	Mar. 30, 2015	Jun. 30, 2014	Dec. 31, 2013	Dec. 31, 2010
Debt Instrument [Line Items]
Amortization of financing costs and discounts				$ 636,000
Notes payable			$ 1,000,000
Promissory note agreed to convert			114,369
Accrued interest paid			$ 39,000
Notes payable and accounts payable, total				$ 950,000
Warrant exercisable as a percentage of shares issued				300.00%
Settlement agreement payment cash paid				$ 265,000
Cash settlement exchange for retiring notes		$ 132,000
Difference amount of notes payable and amount paid to retire						$ 133,000
License agreement and miscellaneous other obligation								$ 23,000
Debt instrument, increase, accrued interest				50,000
Other creditors holding				50,000
Other creditors outstanding principal			95,000
Other creditors outstanding principal				29,000
Accrued interest were repaid by cash				13,000
2013 Securities Purchase Agreement
Debt Instrument [Line Items]
Notes payable				$ 1,000,000
2013 Promissory Note
Debt Instrument [Line Items]
Convertible notes payable current	$ 1,000,000
Proceeds from issuance of preferred stock	$ 1,000,000
Percentage of accrued interest							5.00%
Short term debt maturity date				Jun. 20, 2014
Proceeds from security purchase agreement				$ 364,000
2009 Convertible Notes
Debt Instrument [Line Items]
Convertible notes payable current				$ 426,000
Percentage of accrued interest				24.00%					15.00%
Short term debt maturity date				Sep. 30, 2010
Accrued interest outstanding								$ 396,000
Outstanding convertible note payable					$ 0
Debt and capital lease obligations				$ 194,000
Conversion period				3 years
Debt instrument, face amount				$ 20,000
Debt instrument, increase, accrued interest				$ 29,000
2009 Convertible Notes | CA Warrant
Debt Instrument [Line Items]
Warrant percentage				20.00%
Stock price of warrants				$ 2.44
Warrant expiration date				Sep. 30, 2019
2009 Convertible Notes | PA Warrant
Debt Instrument [Line Items]
Warrant percentage				9.00%
2009 Convertible Notes | 2013 Securities Purchase Agreement
Debt Instrument [Line Items]
Convertible notes payable current			426,000
Accrued interest outstanding			$ 422,000
Side Agreement Notes
Debt Instrument [Line Items]
Convertible notes payable current				$ 249,000
Promissory note agreed to convert				192,341
Series B Preferred Stock
Debt Instrument [Line Items]
Proceeds from security purchase agreement				$ 636,000
Series B Preferred Stock | 2013 Promissory Note
Debt Instrument [Line Items]
Preferred stock shares issued	1,851
Series C Preferred Stock
Debt Instrument [Line Items]
Promissory note agreed to convert			771,458
Common Class A
Debt Instrument [Line Items]
Promissory note agreed to convert			192,865	230,859
Conversion price of common stock				$ 2.44
Exchanged warrants, in share				123,433
Stock price of warrants				$ 2.44
Warrant exchanged					3,052,608
Common stock issued for placement agent commission				34,715
Common stock exercise of warrants purchase of share						32,675
Common stock exercise of warrants purchase price per share						$ 2.44
Common Class A | 2013 Securities Purchase Agreement
Debt Instrument [Line Items]
Notes payable				$ 950,000
Promissory note agreed to convert				389,437
Diluted stock outstanding, percentage				10.00%
Common Class A | 2009 Convertible Notes
Debt Instrument [Line Items]
Promissory note agreed to convert				20,205
Conversion price of common stock				$ 2.44
Exchanged warrants, in share			985,229
Settlement agreement with conversion of common stock				$ 265,000
Common stock conversion price				$ 2.44
Financing closing cost				$ 1,200,000

Commitment and Contingencies -

Commitment and Contingencies - Additional Information (Detail)

Dec. 31, 2016USD ($)

Dec. 31, 2015USD ($)

Jun. 30, 2015USD ($)ft²$ / sharesshares

Jun. 30, 2015USD ($)ft²$ / sharesshares

Dec. 31, 2014USD ($)shares

Mar. 31, 2014USD ($)shares

Jun. 30, 2015USD ($)ft²$ / sharesshares

Jun. 30, 2014USD ($)

Jun. 30, 2015USD ($)ft²$ / sharesshares

Jun. 30, 2014USD ($)

Dec. 31, 2014USD ($)

Apr. 30, 2014USD ($)

Loss Contingencies [Line Items]

Lease Expiration Date

Aug. 31, 2016

Rent expense

$ 87,000

$ 51,000

$ 158,000

$ 99,000

Number of square foot of facility leased. | ft²

[1]

44,681

44,681

44,681

44,681

Extended lease term

[1]

7 years

Base rent

[1]

$ 179,000

Percentage of annual increase of base rent

[1]

3.00%

Research and development

$ 1,745,000

243,000

$ 2,348,000

363,000

Common stock purchased value

70,976,000

Consideration for the sale of the licensed patents

$ 75,000

Notes payable

$ 1,000,000

Ownership interest of the total outstanding common shares

7.00%

Warrant exercise term

10 years

Class of warrant or right outstanding number of shares exercised | shares

37,030

Private placement

$ 70,976,000

$ 3,000,000

Percentage of equity owned by partners

7.00%

Expense earned or paid

$ 0

6,000

6,000

$ 13,000

38,000

Milestone payments

0

0

Fox Chase Cancer Center License Agreement

Loss Contingencies [Line Items]

Expense earned or paid

$ 26,000

$ 50,000

$ 51,000

$ 120,000

Rush University Medical Center License Agreement

Loss Contingencies [Line Items]

Consideration for the sale of the licensed patents

$ 250,000,000

Period of license agreement

12 years

Minimum annual royalty payment

$ 25,000

Payments in license agreement

$ 2,500,000

Common Class A

Loss Contingencies [Line Items]

Exchanged warrants, in share | shares

123,433

123,433

123,433

123,433

Common shares exercise price | $ / shares

$ 2.44

$ 2.44

$ 2.44

$ 2.44

Warrants exchange to purchase common stock | shares

156,109

Purchase of fully-vested incentive stock option | shares

740,600

NantOmics

Loss Contingencies [Line Items]

Initial term of agreement entered into with the related party by the entity

5 years

Related party, agreement renewal term

1 year

NanoCav

Loss Contingencies [Line Items]

Initial term of agreement entered into with the related party by the entity

5 years

Related party, agreement renewal term

1 year

NantCell

Loss Contingencies [Line Items]

Initial term of agreement entered into with the related party by the entity

5 years

Related party, agreement renewal term

1 year

Private Placement One | Sorrento | Common Class A

Loss Contingencies [Line Items]

Common stock, shares sold | shares

4,557,537

4,557,537

Proceeds from issuance of common stock gross of issuance costs

$ 8,000,000

$ 8,000,000

Private Placement Two | Common Class A

Loss Contingencies [Line Items]

Common stock, shares sold | shares

26,252,262

Proceeds from issuance of common stock gross of issuance costs

$ 49,495,000

Private Placement Two | Sorrento | Common Class A

Loss Contingencies [Line Items]

Common stock, shares sold | shares

1,060,789

1,060,789

Common stock purchased value

$ 2,000,000

$ 2,000,000

2013 Securities Purchase Agreement

Loss Contingencies [Line Items]

Notes payable

$ 1,000,000

$ 1,000,000

$ 1,000,000

1,000,000

2013 Securities Purchase Agreement | Common Class A

Loss Contingencies [Line Items]

Notes payable

$ 950,000

$ 950,000

$ 950,000

950,000

Scenario Forecast

Loss Contingencies [Line Items]

Research and development

$ 2,000,000

$ 2,000,000

Sub Lease Agreements

Loss Contingencies [Line Items]

Rent expense

[1]

$ 0

Extended lease term

[1]

1 year

[1]

seven

Out-Licensing Agreement - Addit

Out-Licensing Agreement - Additional Information (Detail) - Intrexon Corporation - USD ($)	1 Months Ended	6 Months Ended
	Feb. 28, 2010	Jun. 30, 2015	Jun. 30, 2014
Licensing Agreement [Line Items]
License agreement term (years)	17 years
Agreement one time fee	$ 350,000
Milestone payment amount		$ 0	$ 0
First IND Filing
Licensing Agreement [Line Items]
Milestone payment amount	50,000
First Phase II Clinical Trial
Licensing Agreement [Line Items]
Milestone payment amount	100,000
First Phase III Clinical Trial
Licensing Agreement [Line Items]
Milestone payment amount	350,000
Commercial Sale Related to Licensed Products
Licensing Agreement [Line Items]
Milestone payment amount	$ 500,000

Spinout of Bank Biologics and35

Spinout of Bank Biologics and Coneksis - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]
Revenue	$ 91	$ 124	$ 211	$ 410
Selling, general and administrative expense	82,429	$ 1,052	114,023	$ 2,113
Bank Biologics | Spinout
Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]
Revenue	7		12
Selling, general and administrative expense	$ 82,387		$ 113,954

Stockholders' Equity - Addition

Stockholders' Equity - Additional Information (Details) $ / shares in Units, $ in Thousands	Jun. 18, 2015USD ($)$ / sharesshares	Jun. 30, 2015USD ($)$ / sharesshares	Apr. 30, 2015USD ($)	Mar. 31, 2015$ / sharesshares	Dec. 31, 2014USD ($)Director$ / sharesshares	Apr. 30, 2014USD ($)shares	Mar. 31, 2014USD ($)	Jun. 30, 2015USD ($)$ / sharesshares	Dec. 31, 2010USD ($)$ / sharesshares	Jan. 01, 2015USD ($)
Class Of Stock [Line Items]
Forward stock split of its outstanding common stock								1.8515
Common stock, shares authorized | shares		100,000,000			80,000,000			100,000,000
Private placement		$ 70,976					$ 3,000
Issuance of common stock less issuance costs of $28								$ 70,976
Promissory note agreed to convert | shares						114,369
Notes payable						$ 1,000
Derivative Liability										$ 177
Proceeds from exercise of warrants								7,134
Repurchase of common stock, value								4,798
Common Stock Warrant
Class Of Stock [Line Items]
Derivative Liability			$ 1,543		$ 177				$ 439
Private Placement
Class Of Stock [Line Items]
Issuance of common stock less issuance costs of $28, Shares | shares		3,698,695
Issuance costs		$ 28
2013 Securities Purchase Agreement
Class Of Stock [Line Items]
Notes payable		$ 1,000						$ 1,000
Common Class A
Class Of Stock [Line Items]
Forward stock split of its outstanding common stock		1
Common stock, shares authorized | shares		0			75,470,414			0
Promissory note agreed to convert | shares						192,865		230,859
Conversion of Class A common stock to common stock, Shares | shares								(65,900,303)
Common stock issued for placement agent commission | shares								34,715
Stock price of warrants | $ / shares		$ 2.44						$ 2.44
Repurchase of common stock, shares | shares	249,952							249,952
Repurchase of common stock, par value | $ / shares	$ 19.20
Repurchase of common stock, value	$ 4,798
Common Class A | Inex Bio Inc
Class Of Stock [Line Items]
Warrants issued to purchase common shares | shares				3,202,593
Stock price of warrants | $ / shares				$ 2
Proceeds from exercise of warrants			$ 6,400
Common Class A | Common Stock Warrant
Class Of Stock [Line Items]
Warrants issued to purchase common shares | shares									114,822
Stock price of warrants | $ / shares		$ 1.76						$ 1.76	$ 2.44
Warrant expiration date								Feb. 29, 2020
Warrant exercisable period								2 years
Percentage of shareholders consent								66.67%
Common Class A | Private Placement One | Sorrento
Class Of Stock [Line Items]
Issuance of common stock less issuance costs of $28, Shares | shares					4,557,537			4,557,537
Common stock issued, par value | $ / shares					$ 1.76
Proceeds from issuance of common stock gross of issuance costs					$ 8,000			$ 8,000
Common Class A | Private Placement Two
Class Of Stock [Line Items]
Issuance of common stock less issuance costs of $28, Shares | shares					26,252,262
Common stock issued, par value | $ / shares					$ 1.89
Proceeds from issuance of common stock gross of issuance costs					$ 49,495
Number of board of directors | Director					9
Common Class A | Private Placement Two | Sorrento
Class Of Stock [Line Items]
Issuance of common stock less issuance costs of $28, Shares | shares					1,060,789			1,060,789
Issuance costs					$ 159
Issuance of common stock less issuance costs of $28					$ 2,000			$ 2,000
Common Class A | 2013 Securities Purchase Agreement
Class Of Stock [Line Items]
Promissory note agreed to convert | shares								389,437
Notes payable		$ 950						$ 950
Conversion of Class A common stock to common stock, Shares | shares								406,048
Common Class A | 2014 Securities Purchase Agreement
Class Of Stock [Line Items]
Commissions								$ 45
Common stock issued for placement agent commission | shares								34,715

Stock-Based Compensation - Addi

Stock-Based Compensation - Additional Information (Details) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended		3 Months Ended		6 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014	Dec. 31, 2014	Apr. 30, 2004
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation expense			$ 80,041	$ 32	$ 104,564	$ 167
Common Class A
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock price of warrants			$ 2.44		$ 2.44
Employee Stock Option
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Aggregate intrinsic value of stock options exercised			$ 14,818
Stock-based compensation expense			2,521	$ 29	$ 3,609	164
Unrecognized compensation cost related to non-vested stock options			$ 27,732		$ 27,732
Weighted-average period for recognition			2 years 8 months 9 days
Employee Stock Option | Common Class A | Officer
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares granted to employee	1,851,500
Shares granted at an exercise price	$ 2.20
Option vesting period	4 years
Warrant Term	4 years
Stock price of warrants	$ 2
Option vested			8,887,200
Employee Stock Option | Common Class A | Officer | Vest over a 40-month service period beginning on April 1, 2015
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Warrants issued to purchase common shares	7,406,000
Employee Stock Option | Common Class A | Officer | Vest based on the achievement of various milestones
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Warrants issued to purchase common shares	10,183,250
Employee Stock Option | Common Class A | Maximum | Officer
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Warrants issued to purchase common shares	17,589,250
Employee Stock Option | 2004 Stock Option Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock reserved for issuance								81,695
Employee Stock Option | 2014 Equity Incentive Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares granted to employee					4,258,449
Shares granted at an exercise price					$ 2.08
Stock option outstanding			8,447,209		8,447,209		5,137,914
Employee Stock Option | 2014 Equity Incentive Plan | Common Class A
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock reserved for issuance		11,109,000
Employee Stock Option | 2014 Equity Incentive Plan | Common Class A | Maximum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Maximum expiration period of grant date fair value of incentive plan		10 years
Non Employee Stock Options
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares granted to employee			0	0
Option vested					73,288
Stock-based compensation expense			$ 1,602	$ 3	$ 2,290	$ 3
Stock option outstanding			354,870		354,870

Stock-Based Compensation - Stoc

Stock-Based Compensation - Stock Option Transactions (Details) - Jun. 30, 2015 - 2014 Equity Incentive Plan - Employee Stock Option - USD ($) $ / shares in Units, $ in Thousands	Total
Number of Shares
Stock Options, Beginning Balance	5,137,914
Shares granted to employee	4,258,449
Stock Options, Options exercised	(949,154)
Stock Options, Ending Balance	8,447,209
Purchase of fully-vested incentive stock option	2,452,979
Weighted Average Exercise Price
Shares granted at an exercise price	$ 2.08
Weighted Average Exercise Price, Options exercised	0.81
Weighted Average Exercise Price, Outstanding Ending balance	1.48
Weighted Average Exercise Price, Vested and Exercisable	$ 0.83
Aggregate Intrinsic Value
Aggregate Intrinsic Value, Outstanding, Ending balance	$ 149,663
Aggregate Intrinsic Value, Vested and Exercisable	$ 45,045
Weighted Average Remaining Contractual Life
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	8 years 1 month 10 days
Weighted Average Remaining Contractual Life, Vested and Exercisable	8 years 11 months 12 days

Stock-Based Compensation - Summ

Stock-Based Compensation - Summary of Options Outstanding and Vested Pricing of Exercise Prices (Details) - Jun. 30, 2015 - Employee Stock Option - 2014 Equity Incentive Plan - $ / shares	Total
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items]
Options Outstanding, Number Outstanding	8,447,209
Options Outstanding, Weighted- Average Life (in Years)	8 years 1 month 10 days
Purchase of fully-vested incentive stock option	2,452,979
Weighted Average Remaining Contractual Life, Vested and Exercisable	8 years 11 months 12 days
$ 0.22
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items]
Exercise Prices	$ 0.22
Options Outstanding, Number Outstanding	1,450,349
Options Outstanding, Weighted- Average Life (in Years)	8 years 8 months 16 days
Purchase of fully-vested incentive stock option	825,468
Weighted Average Remaining Contractual Life, Vested and Exercisable	8 years 8 months 16 days
$ 0.42
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items]
Exercise Prices	$ 0.42
Options Outstanding, Number Outstanding	1,122,859
Options Outstanding, Weighted- Average Life (in Years)	9 years 4 months 24 days
Purchase of fully-vested incentive stock option	869,435
Weighted Average Remaining Contractual Life, Vested and Exercisable	9 years 4 months 24 days
$ 1.76
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items]
Exercise Prices	$ 1.76
Options Outstanding, Number Outstanding	1,615,552
Options Outstanding, Weighted- Average Life (in Years)	9 years 5 months 16 days
Purchase of fully-vested incentive stock option	150,553
Weighted Average Remaining Contractual Life, Vested and Exercisable	9 years 5 months 16 days
$ 2
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items]
Exercise Prices	$ 2
Options Outstanding, Number Outstanding	2,406,949
Options Outstanding, Weighted- Average Life (in Years)	9 years 7 months 13 days
Purchase of fully-vested incentive stock option	491,804
Weighted Average Remaining Contractual Life, Vested and Exercisable	9 years 7 months 13 days
$ 2.20
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items]
Exercise Prices	$ 2.20
Options Outstanding, Number Outstanding	1,851,500
Options Outstanding, Weighted- Average Life (in Years)	3 years 8 months 23 days
Purchase of fully-vested incentive stock option	115,719
Weighted Average Remaining Contractual Life, Vested and Exercisable	3 years 8 months 23 days

Stock-Based Compensation - Blac

Stock-Based Compensation - Black-Scholes Option-Pricing Model to Determine Fair Value of Assumptions Used for Employee Grants and Non-Employee Grants Stock Options (Details) - $ / shares	6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Employee Grants
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected volatility rate	80.00%	91.00%
Dividend yield	0.00%	0.00%
Weighted-average grant date fair value	$ 6.15	$ 0.16
Employee Grants | Minimum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Term of warrants after closing date of the purchase agreement	4 years	5 years
Risk-free interest rate	1.45%	1.58%
Employee Grants | Maximum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Term of warrants after closing date of the purchase agreement	5 years 6 months 7 days	5 years 6 months 7 days
Risk-free interest rate	1.79%	1.89%
Non-Employee Grants
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Term of warrants after closing date of the purchase agreement	10 years	10 years
Risk-free interest rate	2.14%	2.70%
Expected volatility rate	80.00%	91.00%
Dividend yield	0.00%	0.00%
Weighted-average grant date fair value	$ 5.19	$ 0.19

Stock-Based Compensation - St41

Stock-Based Compensation - Stock Based Compensation Expenses Related to Statement of Operations (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation expense	$ 80,041	$ 32	$ 104,564	$ 167
Director Related to Inex Bio, Inc | Warrants for Class A Common Stock to an Officer
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation expense			22,747
Officer | Warrants for Class A Common Stock to an Officer
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation expense	75,918		75,918
Employee Stock Option
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation expense	2,521	29	3,609	164
Non Employee Stock Options
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation expense	1,602	3	2,290	3
Research and Development
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation expense	587		776
Selling, General and Administrative
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation expense	$ 79,454	$ 32	$ 103,788	$ 167

Fair Value Measurement - Schedu

Fair Value Measurement - Schedule of Conclusion Reached (Detail) - USD ($) $ in Thousands	Jan. 01, 2015	Dec. 31, 2014
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Derivative Liability	$ 177
Outstanding Warrants | Significant Unobservable Inputs (Level 3)
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Derivative Liability		$ 177

Fair Value Measurement - Sche43

Fair Value Measurement - Schedule of Assumptions Used For Valuing The Warrants (Detail)	1 Months Ended	12 Months Ended
	Apr. 30, 2015	Dec. 31, 2014
Fair Value Disclosures [Abstract]
Expected dividend yield	0.00%	0.00%
Expected volatility	80.00%	79.50%
Risk-free interest rate	1.43%	1.67%
Marketability discount	10.00%	10.00%

Fair Value Measurement - Sche44

Fair Value Measurement - Schedule of Warrant Liability Measured At Fair Value Using Significant Unobservable Input (Level 3) (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Fair Value Disclosures [Abstract]
Change in fair value of warrant derivative liability	$ 483	$ (6)	$ 1,366	$ 17
Warrant exercised			$ (1,543)

Subsequent Events - Additional

Subsequent Events - Additional Information (Details) $ / shares in Units, $ in Thousands	Jul. 31, 2015USD ($)$ / sharesshares	Jul. 10, 2015	Jul. 08, 2015USD ($)shares	Jun. 30, 2015USD ($)shares	Mar. 31, 2014USD ($)	Jun. 30, 2015shares	Dec. 31, 2014shares
Subsequent Event [Line Items]
Private placement | $				$ 70,976	$ 3,000
Forward stock split of its outstanding common stock						1.8515
Common stock, shares authorized				100,000,000		100,000,000	80,000,000
2015 Equity Incentive Plan | Officer
Subsequent Event [Line Items]
Share-based compensation award vesting rights description						Under the terms of the amended employment agreement, 50% of these awards vest upon grant, and the remaining 50% vest upon the first anniversary of the Company’s initial public offering, subject to continued employment through the applicable vesting dates. The amended employment agreement provides that, commencing as of the first calendar year following the grant of the awards, or in 2015 if the initial public offering does not occur, the executives will be eligible to receive additional annual equity grants as determined by the board of directors or its compensation committee.
Subsequent Event
Subsequent Event [Line Items]
Common stock, shares issued	9,531,200
Proceeds from sale of common stock | $	$ 225,486
Offering Expenses | $	$ 3,000
Forward stock split of its outstanding common stock		1.8515
Subsequent Event | Minimum
Subsequent Event [Line Items]
Common stock, shares authorized	100,000,000
Subsequent Event | Maximum
Subsequent Event [Line Items]
Common stock, shares authorized	500,000,000
Subsequent Event | 2015 Equity Incentive Plan
Subsequent Event [Line Items]
Shares reserved for issuance	3,500,000
Additional Shares reserved for issuance	9,197,066
Subsequent Event | 2015 Equity Incentive Plan | Officer
Subsequent Event [Line Items]
Option to purchase of common stock	900,000
Subsequent Event | 2015 Equity Incentive Plan | Officer | Restricted Stock Units (RSUs)
Subsequent Event [Line Items]
Grants of restricted stock	600,000
Subsequent Event | Private Placement
Subsequent Event [Line Items]
Common stock, shares issued			364,636
Private placement | $			$ 7,000
Subsequent Event | Private Placement One
Subsequent Event [Line Items]
Common stock, shares issued	680,000
Private placement | $	$ 17,000
Subsequent Event | IPO | Officer | Vest over a 40-month service period beginning on April 1, 2015
Subsequent Event [Line Items]
Share-based compensation arrangement, Award Vesting Rights, Percentage		50.00%
Subsequent Event | IPO | Officer | Vest based on the achievement of various milestones
Subsequent Event [Line Items]
Share-based compensation arrangement, Award Vesting Rights, Percentage		50.00%
Subsequent Event | IPO | Officer | Restricted Stock Units (RSUs)
Subsequent Event [Line Items]
Grants of restricted stock	970,300
Subsequent Event | IPO | Officer | Employee Stock Option
Subsequent Event [Line Items]
Granted option to purchase common stock	1,455,450
Shares granted at an exercise price | $ / shares	$ 25